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Abstract 
Glycosaminoglycan (GAG)-protein interactions play important roles in the development 
and maintenance of the nervous system, angiogenesis, spinal cord injury, viral invasion, 
and immune response. Unfortunately, little structural information is available for these 
complexes; indeed, for such important GAGs as the highly sulfated chondroitin sulfate 
motifs, CS-E and CS-D, there are no structural data. This is due to the structural 
heterogeneity of GAGs and the difficulty of obtaining sufficient quantities of material of 
consistent length and sulfation pattern. Here, we describe the development and validation 
of the GAG-Dock computational method to accurately predict the binding poses of protein-
bound GAGs. We validate that GAG-Dock accurately reproduces (< 1 Å RMSD) the 
crystal structure poses for four known heparin-protein structures. Further, we predict the 
pose of heparin and chondroitin sulfate derivatives bound to the axonal guidance proteins: 
protein tyrosine phosphatase σ (RPTPσ) and the Nogo receptor (NgR). Such predictions 
should be useful in understanding and interpreting the role of GAGs in axonal growth and 
other processes. 
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Introduction 
The glycosaminoglycans (GAGs) heparin sulfate (HS) and chondroitin sulfate (CS) are 
involved in a diverse array of physiological processes, such as cell proliferation, migration, 
differentiation, morphogenesis, angiogenesis, blood coagulation, axon guidance, and spinal 
cord injury through interactions with a wide variety of proteins (1-4). Despite the 
importance of GAG-protein interactions, there is remarkably little structural information 
for these complexes. This is due in part to the inherent heterogeneity of GAGs both in 
length and degree of sulfation, and the lack of tools required to obtain homogeneous 
oligosaccharides. GAGs form a family of linear polysaccharides composed of alternating 
uronic acid and hexosamine units. The polysaccharides can vary in length, net charge, 
disaccharide composition, and the pattern and degree of sulfation. The biosynthesis leads to 
distinct sulfation motifs for both CS and HS (Fig. 3-1). Recent studies have shown that 
biological activity is often dependent on the sulfation sequence, with specific, highly 
sulfated sequences directing the interactions of GAGs with growth factors and other 
signaling proteins (5-11). 
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Figure 3-1 – Structures of glycosaminoglycans: heparin, heparin analog, chondroitin sulfates CS-A, CS-C, CS-D, and CS-E 
Obtaining oligosaccharides with defined length and sulfation sequence is a difficult and 
specialized task for highly sulfated HS/heparin, and even more difficult with over-sulfated 
CS motifs such as CS-D and CS-E. As a result, structural data is available for only a 
handful of heparin-protein complexes, and no structural information is available for the CS-
D and CS-E motifs. Recent work has shown that over-sulfated CS and HS interact directly 
with transmembrane receptors such as Nogo receptor (NgR) and type IIa receptor protein 
tyrosine phosphatase s (RPTPs) (11-14). However, it is unclear how GAGs engage and 
activate these receptors.  
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An alternative approach to in vitro structural determination is computational modeling of 
GAG-protein complexes. However, modeling GAG-protein interactions is extremely 
challenging because of the conformational flexibility of GAGs, the high charge density of 
GAGs and GAG-binding sites, and the weak surface complementarity of GAG-protein 
interactions. Despite these challenges, we (7) and others (15-18) have used molecular 
modeling successfully to predict the site at which GAGs engage their target proteins (7, 15-
18). Some of these methods have limited accuracy in predicting the bound pose of the 
ligand or have limited robustness across different systems. Moreover, most of these 
methods have not been applied to systems other than the known heparin-protein structures.  
Herein, we report the GAG-Dock method, that we developed to model accurately GAG-
protein interactions, and we validate this method against known GAG-protein systems.  We 
further apply the method to predict the protein-bound pose of various GAGs, including 
over-sulfated CS, to systems without known structures. 
Summary of the GAG-Dock Method 
Unlike small molecule ligands often docked successfully with various techniques (19-25, 
44), even the truncated GAGs are large (the CS-A 4-mer has 60 heavy atoms and a net 
charge of -4; the CS-E 8-mer has 137 heavy atoms, a net charge of -12). Additionally, they 
bind to protein surfaces rather than in pockets, and engage proteins primarily through 
electrostatic interactions.  
Our new GAG-Dock method is based on the DarwinDock and GenDock methodology (19, 
20) with modifications to accommodate bulky, highly charged, surface-binding ligands 
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characteristic of GAGs. The GAG-binding site is generally not known; hence, it is 
necessary to examine systematically all possible binding regions. To do this, we complete 
two rounds of docking. First, we perform “coarse-level” docking to identify the best 
regions for further study. Second, we carry out “fine-level” docking on the best coarse 
regions to identify specific, strongly bound poses. 
DarwinDock/GenDock  
The DarwinDock/GenDock docking method applied here (19, 20) has been applied 
recently to predict ligand binding sites for GPCRs such as CB1 (21), GLP1-R (22), OR1G1 
(23), TAS2R38 (42), AA3R (24), and 5HT2b-R (25). Briefly it consists of four parts: 
(1) System Preparation. Starting with target protein structures (usually with no hydrogen 
atoms), we prepare the systems as follows: (a) add hydrogens to various heavy atoms using 
standard bond distances and hydrogen binding criteria; (b) assign partial charges to all 
protein atoms based on general force field criteria and to all heteroatoms based on Mulliken 
charges; (c) optimize the protein structure using the force field to minimize the energy; (d) 
replace the 7 bulky, nonpolar residues (V/L/I/M/F/Y/W) with alanine (“alanization”) to 
allow more complete sampling of the binding site; and (e) generate and select regions to be 
sampled by the ligand. 
Generally the conformations of the protein side chains at the ligand binding site depend on 
the location and the conformation of the ligand (the pose), while the location and 
conformation of the ligand depends on the side chain conformations. Our solution to this 
“chicken-egg” problem is to alanize the bulky, nonpolar sidechains in step d (mentioned 
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above) to allow the ligand to fully sample available sites on the protein surface in the 
presence of the polar interactions. After selecting the best poses, the original nonpolar 
sidechains are replaced and reoptimized for each pose using SCREAM (45) in a process we 
call “dealanization”. This allows a different set of protein side chains for each ligand pose. 
To select poses that are close enough to the protein to interact favorably, while not too 
close to clash with protein atoms, we generate spheres to describe the space available for 
the ligand. This is done with the sphgen program (26), modified to work with protein 
surfaces. The spheres are partitioned into overlapping boxes (“sphere regions”) for 
docking. 
(2) Generation of a Complete Set of Poses. Prior to evaluating interaction energies between 
the ligand and protein, we want to sample the complete set of all possible poses. We do this 
by iteratively generating poses and then clustering them into Voronoi-like families using 
RMSD as the distance metric. This is done until the number of families stops changing as 
additional poses are added. For the cases considered here, we used an RMSD criterion of 2 
Å in defining families, which generally leads to ~50,000 poses partitioned into ~2000 
families, for each of which we select the “family head” as the central pose. During the 
pose-generation process no energies are calculated. To choose the best binding region, a 
quick but systematic “coarse” docking is first done using 10,000 poses without attempting 
the iterative, complete sampling. 
(3) Scoring. To reduce computational cost, we want to minimize the number of poses for 
which an energy must be evaluated. Thus, scoring of the poses is broken into two steps. 
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First, the protein-ligand interaction energy of each family head is calculated, and the 
families ranked. Then, 90% of the families are eliminated based on the energy of the family 
head. Finally, the binding energies are calculated for all of the family members (children) 
in these 10% best families, and the poses are ranked with only the best 100 poses selected 
for further analysis. This hierarchical scoring procedure allows for a majority of the poses 
from the complete set (~50,000) to be eliminated without energy calculations. 
(4) Optimization and Refinement. The 100 best poses from step 3 are further optimized and 
refined to identify the best poses. The first step is to de-alanize, i.e., replace and reoptimize 
the “alanized” residues with the full hydrophobic side chains. Simultaneously, all 
sidechains in the binding site are re-optimized (SCREAMed) using the SCREAM side-
chain optimization method (45), in the presence of the specific ligand pose. Thus we end up 
with 100 different sets of side chain conformations, a different set for each ligand pose. 
Then, each of these 100 systems is energy minimized for 10 conjugate gradient steps. At 
this point the 100 poses are rescored and 50% eliminated. Then, another 50 steps of 
minimization are performed for these 50, with the poses again rescored. This final round of 
minimization is skipped during “coarse” docking. 
GAG-Dock Modifications 
The small-molecule docking methodology (DarwinDock/GenDock) was adapted to GAG 
structures through the following changes: 
Sphere generation for flat protein surfaces requires alterations to the standard sphgen 
procedure (26). First, all spheres are generated with the ‘dotlim’ parameter in sphgen set to 
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-0.9, which allows spheres to be generated for flat surfaces. Second, in order to prevent 
the generation of deeply buried spheres that would be inaccessible to GAG ligands, a 
second set of spheres is generated using a probe radius of 2.8 Å instead of the normal 1.4 
Å. The normal (1.4 Å probe radius) set of spheres is compared to the restricted (2.8 Å set), 
and only spheres within 2.8 Å of the restricted set sphere are kept. This procedure allows 
for spheres to be generated for the protein surface, while preventing those spheres from 
being so close to the surface to cause a large number of clashes with the protein during 
pose generation. These spheres are then partitioned into overlapping boxes/regions with 20 
Å sides and 5 Å overlap. 
System Preparation 
All proteins studied here were prepared from PDB structures, with the exception of NgR1, 
NgR2, and NgR3, which required homology modeling from related systems with x-ray 
derived structures.  
GAG Ligand Preparation 
For the four validation systems, a ligand was already present in the crystal structure. 
For the three systems without x-ray structures, no specific binding site is known, and hence 
we selected ligand structures based on the isolated ligands. Thus, the CS-A, CS-D, and CS-
E structures used for docking to the non-validation systems were based on a CS-A 
hexasaccharide crystal structure (28), while the heparin structures for docking to the non-
validation systems are based on a heparin 18-mer NMR structure. For CS-A and heparin, it 
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was only necessary to extend or truncate the structure to the appropriate length. We 
prepared CS-D and CS-E by extending the CS-A structure to a 12-mer, modifying the 
sulfation pattern, optimizing the sidechains, and performing Molecular Dynamics (MD) in 
solution. The structure closest to the average during MD was selected as the conformation 
for docking. This conformation was then truncated to a hexa- or octasaccharide by 
removing sugars from both the reducing and non-reducing ends. This step was necessary 
because the terminal saccharides display high variability in torsion angles during MD that 
are unphysical (inconsistent with possible movements) for an extended polysaccharide. 
Heparin and the other GAGs adopt a helical conformation that distributes charge radially 
along the length of the polysaccharide (31-33). 
Results and Discussion 
In order to validate the GAG-Dock method for such complex ligands and binding sites, we 
applied it to two sets of systems. The first set consists of the four validation systems for 
which a crystal structure including the ligand bound to the specific binding site was known. 
The second set of systems consists of three proteins known to bind to one or more GAG 
ligands, but for which the specific binding site was not known (although the general region 
of binding may be known). In each case, we followed the procedure of (1) coarse docking 
to identify the best regions, and (2) fine docking to identify the best ligand poses. In both 
cases the predicted binding energy was the criterion for selection. 
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Case 1: Validation of systems for which there are x-ray structures of the co-crystal 
Five heparin-protein crystal structures have been solved, providing a means to validate our 
method. We applied GAG-Dock to four of these cases. We did not consider the 5th system, 
FGF1-FGFR2 (PDB: 1E0O (29)), because this 10-mer ligand is significantly more 
demanding computationally, but similar otherwise to the other validation cases.  The 
RMSD comparisons for the predicted and crystal ligands for the validation systems are 
summarized in Table 3-1, showing that GAG-Dock reproduces the ligand positions with 
good accuracy.  Figure S3-13 compares the nonbond interactions between the ligands and 
sidechains within the binding sites of the validation systems.  As can be clearly seen from 
the plots in Fig. S3-13, most of the ligand-sidechain interactions were faithfully 
reproduced.  A major source of error in the sidechain placement and interaction energies 
was the lack of waters in our validation systems.  For structures without known binding 
sites, such as RPTPs and NgR, the placement of waters in an apo-protein crystal structure 
cannot be assumed to be correct for a ligand-bound structure, and even that information is 
lacking if homology modeling is used to generate the protein structure.  Therefore, for a 
realistic assessment of the validation systems, any waters present in the crystal structures 
were removed.  As waters often play a role in ligand binding, removing the waters allows 
sidechains in the protein to interact more strongly with the ligand. 
FGF1 
We validated our method using the crystal structure of the heparin hexasaccharide bound to 
two molecules of fibroblast growth factor 1 (FGF1, PDB: 2AXM (30)). 
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GAG-Dock correctly identified the binding site, with both molecules of FGF1 interacting 
with heparin at the same site, but with different specific residues interacting with the ligand 
for the proteins. The lowest-energy pose was within 0.70 Å root-mean-square deviation 
(RMSD) of the crystal structure ligand (Fig. 3-2A, S3-5, S3-6), calculated by comparing all 
atoms in the docked ligand to all atoms (including added hydrogen atoms) in the x-ray 
ligand. 
Since the crystal structure is available, we docked the protein with all side chains in their 
experimental conformation. In this case we predict the lowest energy (strongest binding) 
ligand pose to have an RMSD error of 0.70 Å. Optimizing the residues for the heparin-
binding site of the FGF1 molecules led to the lowest energy structure with an RMSD of 
2.08 Å for the sidechains compared to the x-ray structure (Fig. S3-5). We consider that this 
is a success. Comparing to the x-ray pose, we find some minor differences in the energy 
contributions (Table S3-5). For example, K112 and K113 in chain A and K128 in chain B 
made stronger Coulomb and hydrogen bonding interactions with the ligand in the docked 
pose than in the x-ray (possibly because the water plays a role in the x-ray structure but not 
in ours). On the other hand, R119 was positioned farther from the ligand in the docked pose 
leading to weaker Coulomb interactions with the ligand. Overall the predicted energy 
contributions for the ligand interacting with each residue were consistent between the 
docked and crystal structures, indicating that these energy contributions can be used to 
understand the relative contributions to binding for each residue of the protein. Our 
conclusion is that our GAG-Dock methodology accurately predicts both the ligand pose 
and the relative importance of residues on the protein toward binding. Our analysis 
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suggests that K112, K113, K118, R122, and K128 make the most important 
contributions to heparin binding.  
FGF2 
For the complex of a heparin tetrasaccharide with FGF2 (PDB: 1BFB (34)), heparin makes 
contacts primarily with a single molecule of FGF2. However, in the crystal there are 
additional contacts with three nearby FGF2 molecules that appear to influence the 
conformation of the ligand. Thus, we docked the heparin tetrasaccharide to the central 
protein while including the three nearby FGFs to describe the conditions of the crystal 
structure. Again, GAG-Dock correctly predicts the binding site and the optimum pose of 
the crystal ligand (0.70 Å RMSD, Fig. 3-2B, S3-7).  
For FGF2, the side chains of the active site differ from the x-ray structure by 2.09 Å 
RMSD. In particular, GAG-Dock predicts conformations of K120, R121, and K130 that 
lead to stronger hydrogen bond and Coulombic contributions to binding than in the x-ray 
structure (Table S3-6).  However for FGF2, no residues had less favorable conformations 
in the docked structure compared to the crystal structure. Again, GAG-Dock correctly 
predicts the relative importance of all residues involved in binding, showing that residues 
K120, R121, K126, K130, and K136 contribute most strongly to heparin binding.  
FGF2-FGFR1 
Heparin is known to form a ternary complex with FGF and its receptor FGFR2. The crystal 
structure of the FGF2-FGFR1-heparin complex features a 2:2:2 stoichiometry (PDB: 1FQ9 
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(35)). In this structure, each heparin molecule (an 8-mer and a 6-mer) binds to the 
positively charged groove formed at the junction of the proteins, making contacts with an 
FGF2 molecule and with the D2 domains of both FGFR1 molecules. Interestingly, this 
structure is very similar to the FGF2-FGFR1 complex without heparin (0.37 Å RMSD 
(36)), suggesting that in this case GAG-Dock correctly predicts the multimeric protein-
receptor-GAG complex (7). We docked both heparin molecules to regions near the FGF1 
molecule and to both FGFR2 molecules. For both heparin molecules, the predicted pose 
correctly identifies the binding pose (with RMSD of 0.75 Å (8-mer) and 1.51 Å (6-mer); 
Fig. 3-2C, S3-8 – S3-11). The RMSD of the side chains in the binding site was 1.76 (8-
mer) and 2.28 Å (6-mer). Again, the predicted pose accounts for the relative importance of 
residues involved in binding, leading to the same pharmacophore identified in the crystal 
structure (Table S3-7 – S3-11).  
α-Antithrombin III 
The interaction between heparin and α-antithrombin III (ATIII) is one of the most studied 
GAG-protein complexes due to its role in blood coagulation (37). The structure of ATIII 
bound to a heparin analog (PDB: 1E03 (38)) provided a more challenging test than the 
other validation cases. With no other protein species making significant contacts to the 
ligand, this structure lacked the constraints of the other validation systems. Even without 
such constraints, GAG-dock predicts the crystal structure pose with 0.60 Å RMSD (Fig. 3-
2D, S3-12). The protein side chains in the binding site have an RMSD of 1.96 Å compared 
to the crystal structure. Again, our predicted pose accounts for the relative importance of 
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residues involved in binding, with residues R13 and K125 contributing more to binding 
in the docked pose (Table S3-12). 
 
Figure 3-2 – Comparison of predicted binding sites for heparin (magenta) to the x-ray crystal ligand positions. (A) FGF1 
[RMSD: 0.70Å], (B) FGF2 [RMSD: 0.70Å], (C) FGF2-FGFR1 [RMSD: 1.51Å, 0.75Å], (D) α-antithrombin III [RMSD: 
0.60Å] 
Table 3-1 – Summary of docking validations.  The resolution of the x-ray structure is given along with the heavy-atom 
RMSD between the predicted and x-ray position of the ligand. 
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Case 2: Predictions for systems for which no co-crystal structure is available  
Unlike heparin, no structural information is available for over-sulfated chondroitin sulfate 
motifs, despite increasing evidence of their biological importance (5, 7, 11, 12, 14). This is 
due to the difficulty in obtaining CS molecules that are purely one type (e.g. CS-E) for use 
in generating crystals.  The recent identification of RPTPs and NgR as mediators of CS-
induced axon inhibition, and the discovery that HS and CS have opposing effects on axon 
morphology (13), highlight the critical need for structural data to facilitate a mechanistic 
understanding of GAG function. Interestingly, both RPTPs and NgR bind to 
polysaccharides enriched in the CS-D, CS-E, or heparin sulfated epitopes, but not the lower 
sulfated motifs, such as CS-A. Thus, these proteins are ideal first systems to test how 
consistent our docking predictions are with in vitro binding data. To this end, we predicted 
docked structures of various GAGs to RPTPs, NgR1, NgR2, and NgR3. 
RPTPs 
While structural data for an RPTPs-GAG complex has not been reported, the GAG binding 
site on the protein is well understood. A defined GAG-binding site lies on the Ig1 domain 
of the protein, mediated by the K67, K68, K70, K71, R96, and R99 residues (13). This 
region forms a shallow electropositive cavity on the surface of the protein between b 
strands C-D and E-F (Fig. S3-14). The quadruple mutation of K67, K68, K70, K71 to 
alanine has been shown to impair binding to both CS and HS (12, 39). ELISA binding data 
to natural GAG polysaccharides indicate that RPTPs binds strongly to the CS-D and CS-E 
motifs and to heparin, but not to CS-A (11,14). To better understand RPTPs-GAG binding, 
we docked CS-E, CS-D, and heparin hexasaccharides to the protein (PDB: 2YD2). We also 
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docked CS-A hexasaccharide but did not find significant binding, which is consistent 
with the lack of binding observed experimentally.  The docked CS-E and heparin structures 
are shown in Fig. 3-3, with detailed structures shown in Fig. S3-15 (CS-E) and S3-16 
(heparin). 
Indeed, GAG-Dock predicts that the GAG ligands bind to the previously identified GAG-
binding site. That is, CS-E and heparin both bound to K67, K68, K71, N73, Q75, R76, 
R96, and R99 (Table S3-14). Additionally, CS-E made contacts with K71 and S74, and 
heparin made contacts with T97. Motifs with lower charge density, such as CS-A, had a 
poor docked scoring energy with the protein compared to CS-E and heparin, suggesting a 
weak interaction in vitro. A continuous tetrasaccharide makes contacts with RPTPs in the 
case of CS-E, while the entire heparin hexasaccharide makes contacts. These data are 
consistent with a single GAG-binding site; however, CS and HS have opposing effects on 
axon growth in DRG neuron cultures. HS promotes axonal growth whereas CS is growth 
inhibitory (13). This raises the question: How is it possible for these structurally related 
ligands to affect such drastically different signaling outcomes? 
Based on size-exclusion chromatography coupled with multi-angle light scattering (SEC-
MALS) using heparin fragments of various lengths and using a CS-A-enriched 
polysaccharide, Coles et al. (13) suggested that the difference between the glycans is that 
HS is capable of clustering RPTPs but CS is not. This is consistent with our GAG-Dock 
predictions (based on docked scoring energies). Later experimental studies demonstrated 
that CS-A has poor affinity to the protein compared to other CS sulfation motifs, especially 
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CS-E (11, 14). Unfortunately, CS-E oligosaccharides of suitable and defined length are 
not readily available to make the appropriate comparison. Nevertheless, it is plausible that 
CS-E polysaccharides should also be capable of simultaneously binding to multiple RPTPs 
molecules. 
However, our docking data suggests another possibility. Because of the higher charge 
density and steeper helical twist of heparin/HS, our predicted pose for heparin 
hexasaccharide exposes several charged groups to the solvent. In contrast, the charged 
groups of CS-E are all engaged with the protein. Therefore, the mechanistic difference 
between heparin and CS-E may be that heparin is able to dimerize RPTPs, just as heparin 
does with FGFs, rather than merely clustering the receptor. Indeed, the SEC-MALS data in 
Coles et al. show that a decasaccharide is capable of binding two molecules of RPTPs, 
suggesting that bound heparin may be able to engage both proteins simultaneously (13). 
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Figure 3-3 – (A) CS-E and (B) heparin bound to RPTPs.  Dotted lines indicate hydrogen bonds to the protein. 
NgR 
The NgRs are myelin-associated inhibitors that restrict axonal growth after injury. A recent 
study demonstrated that NgR1 and NgR3, but not NgR2, are involved in GAG-induced 
axonal inhibition (14). NgRs are comprised of 8.5 leucine-rich repeat (LRR) domains 
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flanked by N-terminal and C-Terminal LRR capping domains and a C-terminal stalk that 
connects the protein to the membrane via a glycosylphosphatidylinositol (GPI) anchor (40). 
Compared to RPTPs, less information is known about how NgR binds to GAGs; however, 
domain deletion studies suggest that the C-terminal capping domain and stalk are required 
for CS binding (14). C-terminal regions of NgR, such as the stalk, have not been resolved 
in the reported crystal structures of the protein (41, 42).  
To better understand the role of the C-terminal domains, we generated homology models of 
NgR isoforms using the ROSETTA software (43). We carried out 5 ns of MD in the 
presence of explicit water and counter ions to allow the 5 models per isoform to relax. We 
then selected the structure nearest to the average conformation for each model, minimized 
it, and then selected the lowest energy structure for each isoform to use in further studies. 
The electrostatic potential surfaces of these homology models of the extracellular domain 
of NgR isoforms 1–3 suggest an electrostatic basis for the difference in activity between 
NgR2 and NgRs 1 and 3 (Fig. S3-17). Unlike the GAG-binding isoforms, NgR2 lacks 
significant regions of electropositive potential. Our predicted binding energies from coarse-
level docking with a CS-E tetrasaccharide to NgR2 led to much weaker interactions (–
297.67 kcal/mol), relative to NgR1 and 3 (–641.27 and –985.46 kcal/mol, respectively), 
consistent with experimental findings. 
Based on fine-level docking with CS-A, -D, -E, and heparin hexasaccharides, followed by 
5 ns MD relaxation in a full water box with counterions, we predict that GAGs bind to 
regions of electropositive potential on the C-terminal cap of both NgR1 and NgR3 (Fig. 3-
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4, S3-18, S3-23). GAG-Dock studies predict that the GAG-binding domains of NgR1 
and NgR3 are on different faces of the C-terminal cap, although this could be due to the 
structural flexibility of this region of the protein and to discrepancies between the model 
and the natural state of the protein. We predict that the GAGs make polar or electrostatic 
contacts with residues R399, R414, R415, R416, R421, K422, R424, R426, and R430 on 
NgR1 (Table S3-15) and with residues R346, R350, K354, N355, N358, R360, K364, 
K399, R400, K401, K403 and R406 on NgR3 (Table S3-16). Many of these residues, 
particularly residues 414–426 on NgR1 and 399–406 on NgR3, were shown by 
mutagenesis studies to be important for GAG binding (14). Together, these results validate 
that GAG-Dock can be used both to understand the structural basis for extreme differences 
in GAG-binding activity between related proteins and to identify reliably the 
pharmacophore even in cases where the protein structure is ill defined.  Detailed structures 
for CS-A, CS-D, CS-E, and heparin bound to NgR1 are shown in Fig. S3-19 – S3-22.  
Detailed structures for those ligand bound to NgR3 are shown in Fig. S3-24 – S3-27. 
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Figure 3-4 – (A) CS-E and (B) heparin bound to NgR1.  (C) CS-E and (D) heparin bound to NgR3. 
Suggested Post-Prediction Validations 
Experimental validation of our novel RPTPs and NgR binding sites may be possible via 
mutation experiments.  We carried out in silico mutations for our predicted CS-A, CS-D, 
CS-E, and heparin binding sites for RPTPs, NgR1, and NgR3 in order to identify 
reasonable suggestions for experimental validation.  Rather than the more common alanine 
mutations, we employed a more subtle mutation to asparagine or glutamine.  As noted 
above, the key interactions between the GAG ligands and the proteins involve arginines 
and lysines.  Mutation of these residues to alanine represents a drastic change in character 
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and could result in significant disruption of the system beyond affecting binding.  
Mutation to asparagine or glutamine allows the possibility of maintaining some polar 
contact with the ligand, but without the benefit of strong charged interactions.  
Additionally, while the standard method is to identify mutations that decrease binding, we 
consider this approach to be ambiguous, as binding can be lost for many reasons.  
Therefore, in addition to the standard loss-of-binding mutations, we identified mutations 
that could potentially increase binding of the ligand to the protein. 
We first employed single-residue mutations of all residues within the binding sites to either 
asparagine or glutamine while simultaneously optimizing the remaining sidechain 
conformations in the binding site using SCREAM, followed by 50 steps of conjugate 
gradient energy minimization.  From these calculations we identified mutations that either 
resulted in additional or lost hydrogen bonding to the ligands.  Based on these individual 
mutations, sets of mutations to either increase or decrease ligand binding were identified 
for each ligand/protein combination.  It should be noted that some mutations of arginine or 
lysine may result in increased hydrogen bonding if the arginine or lysine was initially too 
constrained to make a hydrogen bond to the ligand.  However, such a mutation still remains 
a net loss of overall binding energy due to the lost Coulomb interactions.  Therefore, we 
only considered mutations of arginine or lysine to asparagine or glutamine for our loss-of-
binding mutation sets. 
For RPTPs we identified three sets of mutations that increased binding to CS-A, CS-D, or 
CS-E, but interestingly not to heparin.  It is possible that RPTPs is already optimized for 
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heparin binding, but not for CS binding.  Mutation set “G1” is specific for CS-E, while 
“G2” is specific for CS-D, and “G3” is nonspecific with the exception of decreasing 
heparin binding.  Based on the single residue mutations we generated four sets of mutations 
to decrease binding.  As all of these mutations affect the key arginine and lysine residues, 
they all unsurprisingly result in significant reductions in binding energy.  The mutation sets 
for RPTPs are summarized in Table 3-2, and the single mutations are summarized in Table 
S3-17. 
Table 3-2 – Predicted sets of mutations to either increase (left) or decrease (right) binding of ligands to RPTPs.  Note that 
none of the sets show improved binding for heparin.  Changes in binding energy are shown relative to the wildtype 
structures in both absolute change (kcal/mol) and in terms of percent change. 
 
For NgR1 we identified four sets of mutations to increase binding by building up from the 
single mutation information.  Surprisingly one of the mutation sets (“G3”) did not show 
any improvement in binding when tested.  Set “G1” improved CS-A and CS-D binding, but 
not CS-E or heparin.  Set “G2” improved CS-D and heparin binding.  Set “G4” improved 
binding for every ligand except CS-E.  It is again interesting that none of the mutation sets 
improved CS-E binding.  As with RPTPs, the four loss-of-binding mutation sets were all 
effective in reducing ligand binding, but were non-specific for any ligand.  The mutation 
Set CSA CSD CSE HEP Mutations Set CSA CSD CSE HEP Mutations
G1 -1.7 -0.3 -34.2 30.5 V73N	S75N	Q76N	F78Q	 L1 565.5 719.2 709.8 1059.6 K68Q	K69N	K71Q	R77N	R97N	R100N	
G2 -6.2 -35.0 12.6 29.7 N74Q	S75N	 L2 386.0 528.2 481.5 705.1 K71N	R77Q	R97N	R100Q	
G3 -17.8 -23.8 -29.0 21.2 V73Q	S75N	Q76N	F78N	N103Q	 L3 383.5 472.6 458.7 657.3 K68N	K69Q	R77N	R100N	
L4 468.6 629.7 603.3 891.1 K68N	K71Q	R77N	R97N	R100Q	
Set CSA CSD CSE HEP Mutations Set CSA CSD CSE HEP Mutations
G1 0.3 0.0 4.2 -2.9 V73N	S75N	Q76N	F78Q	 L1 -97.3 -92.8 -87.8 -101.0 K68Q	K69N	K71Q	R77N	R97N	R100N	
G2 1.1 4.5 -1.6 -2.8 N74Q	S75N	 L2 -66.4 -68.1 -59.6 -67.2 K71N	R77Q	R97N	R100Q	
G3 3.1 3.1 3.6 -2.0 V73Q	S75N	Q76N	F78N	N103Q	 L3 -66.0 -61.0 -56.7 -62.7 K68N	K69Q	R77N	R100N	
L4 -80.6 -81.2 -74.6 -84.9 K68N	K71Q	R77N	R97N	R100Q	
PTPS	-	Increased	Binding	(Relative	Energy) PTPS	-	Loss	of	Binding	(Relative	Energy)
PTPS	-	Increased	Binding	(Percent	Change) PTPS	-	Loss	of	Binding	(Percent	Change)
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sets for NgR1 are summarized in Table 3-3, and single mutations are summarized in 
Table S3-18. 
Table 3-3 – Predicted sets of mutations to either increase (left) or decrease (right) binding of ligands to NgR1.  Note that 
none of the sets show improved binding for CS-E.  Changes in binding energy are shown relative to the wildtype structures 
in both absolute change in binding energy (kcal/mol) and in terms of percent change. 
 
Each of the mutation sets to increase binding for NgR3 show improved binding to at least 
one of the ligands.  None of the ligands is completely missed as heparin was for RPTPs or 
CS-E for NgR1.  The mutation sets for NgR3 are summarized in Table 3-4, and single 
mutations are summarized in Table S3-19. 
Set CSA CSD CSE HEP Mutations Set CSA CSD CSE HEP Mutations
G1 -15.8 -14.0 2.7 -3.6 C395Q	C405N	 L1 481.3 607.0 649.0 850.0 R390N	R391N	R392Q	R402N	R406N	
G2 10.6 -30.8 4.2 -38.0 S396N	N399Q	C405N	 L2 471.5 627.0 597.9 813.1 R390Q	R391Q	R400N	R402N	R406N	
G3 -0.1 0.4 10.5 -1.1 C395Q	S396N	S403Q	C405Q	 L3 382.4 463.0 580.7 610.0 R391N	R392Q	R402Q	R406Q	
G4 -20.9 -19.6 9.8 -27.1 S396Q	C405N	 L4 473.2 629.9 642.9 834.1 R390N	R392Q	R400N	R402Q	R406N	
Set CSA CSD CSE HEP Mutations Set CSA CSD CSE HEP Mutations
G1 2.2 1.4 -0.3 0.3 C395Q	C405N	 L1 -65.3 -62.0 -71.3 -75.8 R390N	R391N	R392Q	R402N	R406N	
G2 -1.5 3.1 -0.5 3.4 S396N	N399Q	C405N	 L2 -64.0 -64.1 -65.7 -72.5 R390Q	R391Q	R400N	R402N	R406N	
G3 0.0 0.0 -1.2 0.1 C395Q	S396N	S403Q	C405Q	 L3 -51.9 -47.3 -63.8 -54.4 R391N	R392Q	R402Q	R406Q	
G4 2.9 2.0 -1.1 2.4 S396Q	C405N	 L4 -64.2 -64.3 -70.6 -74.4 R390N	R392Q	R400N	R402Q	R406N	
NGR1	-	Increased	Binding	(Relative	Energy) NGR1	-	Decreased	Binding	(Relative	Energy)
NGR1	-	Increased	Binding	(Percent	Change) NGR3	-	Decreased	Binding	(Percent	Change)
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Table 3-4 – Predicted sets of mutations to either increase (left) or decrease (right) binding of ligands to NgR3. Changes 
in binding energy are shown relative to the wildtype structure in both absolute change (kcal/mol) and in terms of percent 
change. 
 
Conclusions 
Predicting the binding sites of highly charged GAG ligands with multiple independent 
charge sites and numerous possible conformations seems a formidable challenge. The very 
large number of charged sites on the ligands and in the binding site likely leads to 
redistributions of the water and ions in the solvent making polarization likely of great 
importance. Nevertheless, we show for eight independent systems that the simple GAG-
Dock modifications of the DarwinDock general docking approach accounts well for the 
enormous importance of electrostatic interactions, leading to plausible structures and 
relative binding energies that help distinguish the strength of binding for various GAG 
ligands to a wide variety of receptors likely to play essential roles in axonal growth. Given 
the difficulty of obtaining high quality co-crystals for x-ray studies, this simple GAG-Dock 
computational methodology may provide the best means for predicting the structure 
sufficiently accurately to help design experimental probes to elucidate the issues 
controlling axonal growth, perhaps suggesting modified ligands that might be more 
selective and controllable. 
Set CSA CSD CSE HEP Mutations Set CSA CSD CSE HEP Mutations
G1 -15.9 6.9 -9.9 -10.1 I345Q	A348N	 L1 230.6 271.2 327.7 396.5 K331N	K334Q	R342N	
G2 -3.1 0.8 -10.2 -0.1 I345Q	 L2 321.9 537.6 545.0 802.2 K331N	R342N	R380N	R381N	R383N
G3 -12.9 -5.1 -5.8 -12.2 A348N	 L3 470.9 771.7 858.4 1054.7 R330N	K331N	K334N	R342N	R380Q	K381N	K383N
G4 -7.7 1.9 7.9 -23.7 N338Q	A348N	 L4 238.0 413.9 425.4 644.0 R340N	R379N	R380N	R383N
Set CSA CSD CSE HEP Mutations Set CSA CSD CSE HEP Mutations
G1 2.2 -0.6 0.8 0.7 I345Q	A348N	 L1 -31.3 -23.6 -27.0 -25.9 K331N	K334Q	R342N	
G2 0.4 -0.1 0.8 0.0 I345Q	 L2 -43.7 -46.8 -44.9 -52.4 K331N	R342N	R380N	R381N	R383N
G3 1.8 0.4 0.5 0.8 A348N	 L3 -63.9 -67.1 -70.7 -68.9 R330N	K331N	K334N	R342N	R380Q	K381N	K383N
G4 1.0 -0.2 -0.6 1.5 N338Q	A348N	 L4 -32.3 -36.0 -35.0 -42.1 R340N	R379N	R380N	R383N
NGR3	-	Increased	Binding	(Relative	Energy) NGR3	-	Decreased	Binding	(Relative	Energy)
NGR3	-	Increased	Binding	(Percent	Change) NGR3	-	Decreased	Binding	(Percent	Change)
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Supplementary Information 
System Preparation 
Crystal structures & PTPσ . Protein molecules within 5 Å of the GAG ligand, if present, 
were selected from the PDB. Hydrogen atoms were added with tleap (S23) and CHARMM 
(S1) charges were assigned to each atom. The system was minimized using the DREIDING 
force field (S2). 
NgR. Five homology models for full-length NgR1, 2, and 3 were obtained using 
ROSETTA (S3). Each model was minimized (5000 steps) and allowed to relax in the 
presence of water and counterions with 5 ns of MD. MD was performed using NAMD in 
four steps, as described later in the MD section. Briefly, first, a water box bounding the 
protein was minimized with the protein kept fixed. Second, 0.5 ns of NPT MD were 
performed on the water box. Third, the entire systems were minimized. Finally, 5 ns of 
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NPT MD were performed on the entire system. For each initial conformation, the 
conformation closest to the average structure from the 5 ns MD was minimized and the 
lowest-energy conformation was selected for each isoform.  
DarwinDock 
The concept behind DarwinDock (S4-S12) is (1) to generate a complete set of poses for the 
binding site while minimizing the number of energy evaluations, (2) then to collect these 
into a smaller sets containing all poses likely to be important, (3) then to evaluate the 
binding energy of this relatively small set to find the best poses, while ensuring that no 
poses are missed that might prove to be important.  
Pose generation is accomplished by iteratively generating poses (but no energies) using 
DOCK 6 (S13) and clustering them into families using our Closest-Neighbor Seeded 
clustering algorithm (described below). Our usage of DOCK 6 is very simplistic, utilizing 
only the bump filter. We follow the default settings for generating the bump grid for 
DOCK 6 and set the bump cutoff to 5. Two calls to DOCK 6 are generally made. First, a 
request for 40,000 poses is made to determine the approximate percentage of poses that 
will pass the DOCK bump filter. Then a second request for poses is made, based on the 
percent of poses passing the bump test so that enough poses are returned to be sufficient for 
the iterative completeness cycle. Initially the first 5000 poses are clustered with a 2 Å 
diversity, then the next 5000 poses are added and reclustered, leading an increased number 
of families. This process is continued in increments of 5000 poses until the number of new 
families represents less than 5% of the total number of families at that point. 
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Due to the computational difficulty of dealing with GAG ligands – which are 
considerably larger than normal small-molecule ligands for which DarwinDock was 
developed – leading to correspondingly increased search volumes, we restrict the number 
of poses during this iterative completeness cycle to 50,000. Furthermore, it is generally not 
possible to request more than 15 million poses (sometimes fewer) from DOCK6 before 
memory limitations intercede. As a result, most regions reach the 50,000 pose limit before 
reaching the 5% new families threshold. Other regions may fall well short of 50,000 poses 
due to their geometry and memory limitations. 
After generating a complete set of poses, or the largest set within our computational limits, 
we score all family heads (generally ~2000). For each family the central pose (based on the 
RMSD) is denoted as the family head. The protein-ligand interaction energy of each family 
head is evaluated using the DREIDING forcefield (S2) with MPSim (S14). DREIDING 
partitions non-bond energies into Coulomb, hydrogen-bond, and Van Der Waals (VDW). 
For GAG-Dock the interaction energy is the sum of all ligand-protein Coulomb and 
hydrogen-bond energies plus 10% of the (VDW) energy. Including only 10% of the VDW 
energy allows for strong polar interactions with the protein with moderate clashes that can 
be resolved during sidechain optimization. Not including the VDW energy results in poses 
with severe, unresolvable clashes with the protein, while including the full VDW energy 
results in poses that are too far from the protein and make poor contact. 
After evaluating the interaction energy for the family heads, we eliminate the worst 90% of 
the families. Next, we evaluate the interaction energy for all children in the remaining 10% 
of families. From these children we select best 100 based on binding energy. Eliminating 
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90% of the families without evaluating all of their child poses allows for a large fraction 
of the complete set of poses to be eliminated without the time-consuming energy 
evaluation. 
The 100 selected poses are then further refined with sidechain optimization using 
SCREAM (S15). Any sidechain that was alanized prior to docking is now restored and 
optimized (“de-alanized”) by SCREAM. Simultaneously, any polar or charged sidechain in 
the binding site is also optimized by SCREAM, resulting in 100 unique sets of sidechain 
conformations each adapted to a specific ligand pose. Each complex is then energy 
optimized for 10 steps of conjugate gradient minimization. The minimized complexes are 
then scored using the “snap” binding energy, which is the total energy of the protein and 
the total energy of the ligand subtracted from the total energy of the complex, all calculated 
using DREIDING and MPSim. We then eliminated half of these complexes based on these 
energies. The remaining half was optimized with an additional 50 steps of conjugate 
gradient minimization. These fully-minimized complexes were rescored again, and the top 
one or two poses identified for analysis. 
Closest-Neighbor Seeded Ligand Clustering 
The Closest-Neighbor Seeded (CNS) ligand clustering algorithm uses a RMSD-based 
metric to cluster ligands into families and to assign family heads. First, all pairwise ligand 
RMSDs were calculated (ignoring hydrogen atoms). These pairwise RMSDs were placed 
in a list ordered from smallest RMSD to largest. The pair of ligands with the smallest 
RMSD constitutes the seed for the first family/cluster. Proceeding down the list of pairs i 
and j, the following operations were carried out: 
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1. If pose i and pose j do not belong to a pre-existing family, then a new family is 
seeded 
2. If pose i belongs to family A and pose j does not belong to a family (or vice versa): 
If the RMSD of pose j to all members of family A is less than the diversity RMSD, 
then pose j is added to family A 
3. If pose i belongs to family A and pose j belongs to family B: If the RMSD of pose i 
to all members of family B is less than the diversity RMSD, and if the RMSD of 
pose j to all members of family A is less than the diversity RMSD, then the two 
families are merged into a single family 
The pose with the lowest RMSD to the rest of the members is designated as the family 
head. If a family only has two members then the family head is chosen randomly. 
Forcefield 
All forcefield calculations during docking – with the exception of sidechain optimizations – 
were performed using the DREIDING (S2) forcefield and the MPSim (S14) molecular 
dynamics code. DREIDING uses a three body hydrogen bond term that allows a more 
precise analysis of the energetics. It also eliminates the need of SHAKE constraints that 
must be used with the 2-body hydrogen bonds used in most force fields 
Sidechain Optimization 
Sidechain optimization was performed using the SCREAM program (using the DREIDING 
forcefield. 
Sphere Generation 
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Spheres were generated using a modified sphgen program (S13). Specifically, two sets of 
spheres were generated for each protein: 
The “normal” set: 
• Use a 1.4 Å probe radius in the dms molecular surface program (44) 
• Use dotlim=–0.9 in sphgen 
• Use 1.4 Å minimum and 10 Å maximum sphere radii in sphgen 
The “restriction” set: 
• Use 2.8 Å probe radius in dms 
• Use dotlim=–0.9 ’ in sphgen 
• Use 2.8 Å minimum and 10 Å maximum sphere radii in sphgen 
The final set of spheres is taken from the “normal” set with the criteria that a sphere must 
be within 2.8 Å of a sphere from the “restriction” set. 
The final set of spheres was partitioned into overlapping boxes having 20 Å sides and 
allowing 5 Å overlap.  
As mentioned above, we assign electrostatic potential values to the spheres. The 
electrostatic potential for the protein is generated using APBS (S16-S18) and mapped onto 
the generated spheres. The electrostatic potential for a given sphere is taken from the value 
from the nearest APBS grid point. 
Sphere Clustering 
In order to reduce the number of spheres in each region to a computationally-manageable 
number, the spheres are clustered using the CNS algorithm, with each sphere treated as a 
single-atom ligand. The clustering diversity is set at 0.25 and increased until the total 
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number of families is less than 150, or until the diversity is 3.00. For sphere families with 
3 or more spheres, the family head is kept to represent the family. For sphere families of 2 
spheres, the coordinates are averaged. 
Ligand Preparation  
All crystal structure ligands were prepared by identifying the appropriate DREIDING atom 
types and assigning Mulliken charges from Density Functional Theory (DFT) calculations 
using the B3LYP level of theory and the 6-311G** basis set in Jaguar (S19, S27).  
Heparin and CS ligands for the predicted systems (RPTPs, NgR, EphB2, and EphB3) were 
generated from available 18-mer heparin NMR structures (S20) and a 6-mer CS-A (S21) 
crystal structure as mentioned above. The heparin and CS-A structures were truncated or 
extended as needed for docking. Generating CS-D and CS-E required modifying the 
sulfation pattern of an extended 12-mer CS-A structure. 
The sulfation pattern was modified using the Maestro software, Mulliken charges were 
calculated, and the MacroModel (S22) Conformational Search tool was used to sample the 
sidechain torsions (the sugar backbone was kept fixed). The resulting conformations were 
minimized using DREIDING and MPSim with Surface Generalized Born (SGB) solvation. 
The lowest-energy conformation was then selected for MD. 
The AMBER (S23) package was used to place the 12-mer in a water box with a number of 
sodium ions added to neutralize the ligand charge. Dynamics was performed using NAMD 
(S24) in four steps as described in the next section. Briefly, first, the water box was 
minimized with the ligand kept fixed. Second 0.5 ns of MD were performed on the water 
box. Third, the entire system was minimized. Finally, 5 ns of MD were performed on the 
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entire system. The final ligand conformation for docking was the conformation closest to 
the average structure from the 5 ns MD. The 12-mer was truncated for docking by 
removing the terminal sugars. 
Molecular Dynamics (MD) 
The MD simulations were carried out using NAMD (S24), a parallel MD code designed for 
computationally demanding biomolecular systems. The CHARMM (S1) force field was 
used for the protein and ligands. The TIP3P (S25) force field was used for water. NAMD 
employs periodic boundary conditions to remove surface effects. The full electrostatic 
interactions within this periodic system is calculated using the particle-mesh Ewald 
summation method (S26). The long-range electrostatic and van der Waals interactions were 
cut off at 12 Å (with spline smoothing). 
The calculations were performed under isothermal-isobaric conditions (NPT) at 310 K and 
1 atm. The temperature was controlled using Langevin dynamics (with a coupling 
coefficient of 5 ps-1) and the pressure is maintained using a Langevin-Hoover barostat. A 
time step of 1 fs was used throughout this study. 
Simulations. The MD is carried out in 4 steps: 
a) The water atoms and counter-ions were conjugate gradient minimized for 5000 steps 
while keeping the protein and ligand atoms fixed. This allows for the water and counter 
ions to remove any bad contacts with each other and the protein or the ligand, prior to 
MD. 
b) Then the water and counter-ion atoms were equilibrated under NPT conditions (310 K 
and 1 atm) for 0.5 ns, while keeping the protein and ligand fixed. This allows the lipids 
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and waters to equilibrate in the presence of the protein and to fill any gaps around the 
protein created due to system setup. 
c) Next, the full system (protein-ligand-water) was minimized for 5000 steps, allowing the 
protein and ligand to adjust to the equilibrated water and counter ions. 
d) Finally, the full system is equilibrated for at least 5 ns under NPT conditions, of which 
only the last 5 ns is used for dynamical analysis. Snapshots are saved every 1 ps. 
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Supplemental Figures & Tables 
 
Figure S3-5 – Structure of FGF1 [PDB: 2AXM, resolution 3.00 Å] with predicted and crystal heparin hexamer ligands 
(magenta: predicted, green: crystal).  Residues in the binding site with significant deviations from the crystal are labeled 
(cyan: predicted, orange: crystal). Ligand RMSD is 0.70 Å. 
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Figure S3-6– Structure of FGF1 [PDB: 2AXM, res. 3.00 Å] with predicted heparin hexamer ligand (magenta) and 5 Å 
binding site shown (cyan).  Dashed lines indicate hydrogen bonding and salt bridges between ligand and protein.  The 
predicted ligand has excellent agreement with the crystal ligand, RMSD: 0.70 Å. 
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Figure S3-7 – Structure of FGF2 [PDB: 1BFB, res. 1.90 Å] with predicted heparin tetramer ligand (magenta) and 5 Å 
binding site shown (cyan).  Dashed lines indicate hydrogen bonding and salt bridges between ligand and protein.  The 
predicted ligand has excellent agreement with the crystal ligand, RMSD: 0.70 Å. 
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Figure S3-8 – Structure of FGF2-FGFR1 [PDB: 1FQ9, res. 3.00 Å] chain A with predicted heparin hexamer ligand 
(magenta) and 5 Å binding site shown (cyan).  Dashed lines indicate hydrogen bonding and salt bridges between ligand 
and protein.  The predicted ligand has excellent agreement with the crystal ligand, RMSD: 1.51/0.75 Å. 
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Figure S3-9 – Structure of FGF2-FGFR1 [PDB: 1FQ9, res. 3.00 Å] chain B with predicted heparin hexamer ligand 
(magenta) and 5 Å binding site shown (cyan).  Dashed lines indicate hydrogen bonding and salt bridges between ligand and 
protein.  The predicted ligand has excellent agreement with the crystal ligand, RMSD: 1.51/0.75 Å. 
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Figure S3-10 – Structure of FGF2-FGFR1 [PDB: 1FQ9, res. 3.00 Å] chain C with predicted heparin hexamer and octamer 
ligands (magenta) and 5 Å binding site shown (cyan).  Dashed lines indicate hydrogen bonding and salt bridges between 
ligand and protein.  The predicted ligand has excellent agreement with the crystal ligand, RMSD: 1.51/0.75 Å. 
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Figure S3-11 – Structure of FGF2-FGFR1 [PDB: 1FQ9, res. 3.00 Å] chain C with predicted heparin hexamer and octamer 
ligands (magenta) and 5 Å binding site shown (cyan).  Dashed lines indicate hydrogen bonding and salt bridges between 
ligand and protein.  The predicted ligand has excellent agreement with the crystal ligand, RMSD: 1.51/0.75 Å. 
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Figure S3-12 – Structure of α-Antithrombin-III [PDB: 1E03, res. 2.90 Å] with predicted heparin analog pentamer ligand 
(magenta) and 5 Å binding site shown (cyan).  Dashed lines indicate hydrogen bonding and salt bridges between ligand and 
protein.  The predicted ligand has excellent agreement with the crystal ligand, RMSD: 0.60 Å. 
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Figure S3-13 – Plots of nonbond energies for residues in the (A) FGF1, (B) FGF2, (C) FGF2-FGFR1 Chain A complex, 
(D) FGF2-FGFR1 Chain B complex, and (E) α-Antithrombin-III binding sites in complex with a heparin ligand in the 
crystal versus docked structure. Residues with significant deviations from the trend are labeled. 
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Table S3-5 – Per-residue energetic contributions in the FGF1/heparin predicted (left) and crystal (right) structures. 
[PDB: 2AXM, res. 3.00 Å, RMSD: 0.70 Å]. 
 
Table S3-6 – Per-residue energetic contributions in the FGF2/heparin predicted (left) and crystal (right) structures. [PDB: 
1BFB, res. 1.90 Å, RMSD: 0.70 Å]. 
 
Docked Crystal 
  Residue VdW Coulomb H Bond NonBond VdW Coulomb H Bond NonBond ΔNonBond 
C
ha
in
 A
 
LYS 113 17.56 -204.76 -15.75 -202.95 2.77 1.19 -2.00 1.96 -204.91 
LYS 118 3.22 -189.23 -5.96 -191.97 -0.56 4.09 0.00 3.54 -195.51 
LYS 112 3.29 -183.50 -3.81 -184.01 -0.33 -143.67 0.00 -144.00 -40.01 
ARG 122 7.16 -169.14 -9.33 -171.31 3.14 -153.18 -3.12 -153.17 -18.14 
LYS 128 3.06 -148.57 -1.85 -147.37 -0.41 4.77 0.00 4.37 -151.74 
ARG 119 -0.11 -91.00 0.00 -91.11 -0.06 -3.21 0.00 -3.27 -87.84 
GLN 127 -2.00 -8.03 0.00 -10.03 -1.99 -186.44 -1.59 -190.03 180.00 
ALA 129 5.47 -10.00 -4.60 -9.14 -0.38 -122.47 0.00 -122.86 113.72 
ASN  18 2.01 -1.44 -5.71 -5.13 -1.52 -165.54 -1.67 -168.72 163.59 
ILE 130 -0.32 -3.07 0.00 -3.39 -0.88 5.58 0.00 4.70 -8.08 
GLY 115 -0.04 -3.22 0.00 -3.27 -0.13 -6.95 0.00 -7.08 3.81 
GLY 126 -0.87 3.54 0.00 2.66 -4.08 -140.24 -1.57 -145.89 148.55 
LEU 111 -0.48 3.51 0.00 3.03 3.28 -8.41 -1.05 -6.18 9.21 
ASN 114 -0.23 3.33 0.00 3.10 -0.30 -2.97 0.00 -3.28 6.38 
C
ha
in
 B
 
LYS 113 4.89 -197.61 -9.67 -202.39 1.11 -215.76 -5.84 -220.49 18.10 
LYS 112 4.24 -198.73 -5.46 -199.96 2.69 -190.94 -0.44 -188.69 -11.26 
LYS 118 11.00 -197.81 -5.73 -192.53 -4.61 -181.97 0.00 -186.58 -5.96 
ARG 122 4.88 -176.18 -10.38 -181.68 2.69 -175.17 -1.89 -174.37 -7.31 
LYS 128 10.38 -181.92 -6.98 -178.52 2.06 -135.42 0.00 -133.36 -45.16 
ARG 119 7.42 -125.16 -5.83 -123.58 -2.11 -111.44 0.00 -113.55 -10.03 
ASN 114 5.11 -22.15 -10.47 -27.51 -0.34 -7.68 -1.92 -9.94 -17.57 
GLN 127 2.94 -13.43 -1.56 -12.05 -0.60 -5.77 0.00 -6.37 -5.68 
ALA 129 6.73 -10.22 -4.49 -7.99 -0.14 -3.90 0.00 -4.04 -3.94 
GLY 115 -0.14 -4.03 0.00 -4.17 -0.27 -2.84 0.00 -3.11 -1.07 
ILE 130 -0.37 -3.13 0.00 -3.50 -1.63 2.88 -3.24 -1.99 -1.50 
ASN  18 0.24 2.05 -5.05 -2.76 -2.38 1.24 -0.18 -1.32 -1.44 
GLY 126 -0.24 2.42 0.00 2.18 -0.56 2.92 0.00 2.36 -0.17 
LEU 111 -0.72 2.97 0.00 2.25 -0.25 2.86 0.00 2.61 -0.36 
Docked Crystal 
  Residue VdW Coulomb H Bond NonBond VdW Coulomb H Bond NonBond ΔNonBond 
C
ha
in
 A
 
ARG 121 17.30 -158.68 -12.19 -153.56 -0.27 -150.23 -0.96 -151.45 -2.11 
LYS 126 9.10 -156.65 -0.36 -147.92 -3.44 -119.39 -2.31 -125.14 -22.78 
LYS 130 10.15 -144.73 -8.56 -143.15 -5.00 -107.74 -1.75 -114.49 -28.65 
LYS 120 8.16 -140.09 -5.58 -137.52 -2.88 -101.57 0.00 -104.45 -33.07 
LYS 136 6.73 -135.14 -5.78 -134.19 -0.75 -85.16 0.00 -85.91 -48.28 
LYS  27 -0.42 -87.54 0.00 -87.96 -0.28 -75.32 0.00 -75.60 -12.37 
GLN 135 2.17 -18.79 -6.09 -22.72 -2.77 -2.99 0.00 -5.76 -16.96 
ALA 137 7.94 -9.51 -3.59 -5.16 5.61 -8.31 -2.66 -5.37 0.21 
ILE 138 -0.28 -2.34 0.00 -2.62 -2.44 1.25 -1.53 -2.72 0.10 
ASN  28 3.07 -1.79 -3.76 -2.47 -0.28 -2.29 0.00 -2.57 0.10 
THR 122 -0.40 0.02 0.00 -0.37 -0.31 -1.32 0.00 -1.63 1.26 
GLY 134 -0.37 2.18 0.00 1.81 -0.43 2.34 0.00 1.92 -0.11 
LEU 119 -0.62 4.44 0.00 3.82 -0.45 4.03 0.00 3.57 0.25 
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Table S3-7 – Per-residue energetic contributions in the FGF2-FGFR1/heparin predicted (left) and crystal (right) 
structures for chains A and B. [PDB: 1FQ9, res. 3.00 Å, RMSD: 1.51/0.75 Å]. 
Docked Crystal 
Residue VdW Coulomb H Bond NonBond  VdW Coulomb H Bond NonBond ΔNonBond 
C
ha
in
 A
 
ARG 120 -2.28 -149.49 -5.26 -157.04 1.52 -152.06 -7.27 -157.81 0.77 
LYS 135 1.54 -139.58 -5.91 -143.95 4.60 -153.99 -3.79 -153.18 9.24 
LYS 119 0.67 -131.00 -4.78 -135.12 3.14 -130.93 -0.25 -128.04 -7.08 
LYS 125 5.84 -131.09 -5.87 -131.11 0.62 -116.95 -0.65 -116.98 -14.13 
LYS  26 4.39 -120.65 -5.68 -121.94 -1.02 -109.45 0.00 -110.47 -11.47 
LYS 129 4.99 -114.65 -5.58 -115.25 -1.24 -107.92 -0.68 -109.84 -5.41 
ALA 136 -0.53 -3.71 0.00 -4.24 2.86 -6.00 -4.60 -7.74 3.51 
GLY  28 -0.37 -2.08 0.00 -2.45 -2.02 1.97 -3.62 -3.67 1.22 
ILE 137 -0.12 -1.95 0.00 -2.07 -0.66 -1.95 0.00 -2.61 0.53 
GLN 134 -1.91 0.68 0.00 -1.23 -0.29 -2.08 0.00 -2.36 1.14 
ASN  27 -1.89 2.20 0.00 0.31 -0.48 -1.59 0.00 -2.08 2.39 
THR 121 -0.20 0.54 0.00 0.34 -0.17 -1.53 0.00 -1.70 2.04 
TYR  24 -0.14 1.63 0.00 1.49 4.63 -4.77 0.00 -0.14 1.63 
LEU 118 -0.15 2.35 0.00 2.20 -0.31 2.16 0.00 1.85 0.35 
GLY 133 -0.32 2.55 0.00 2.23 -0.50 2.69 0.00 2.19 0.04 
LEU 126 -0.14 2.56 0.00 2.42  -0.28 2.62 0.00 2.34 0.08 
C
ha
in
 B
 
LYS 135 1.19 -212.03 -6.46 -217.30 -8.49 -203.03 -1.48 -212.99 -4.31 
ARG 120 -6.58 -199.88 -1.36 -207.81 31.40 -208.27 -3.53 -180.39 -27.41 
LYS 125 5.60 -182.56 -6.84 -183.80 38.12 -175.56 -3.61 -141.05 -42.75 
LYS 119 12.36 -181.40 -10.45 -179.49 -2.14 -138.68 0.00 -140.82 -38.67 
LYS 129 -1.92 -141.31 -0.25 -143.48 -1.59 -130.86 0.00 -132.44 -11.04 
LYS  26 -2.18 -138.89 0.00 -141.07 37.15 -138.94 0.00 -101.78 -39.29 
GLN 134 -2.27 -6.73 0.00 -9.00 9.71 -20.50 -3.13 -13.92 4.92 
ALA 136 -1.24 -7.10 0.00 -8.34 -1.58 -6.76 0.00 -8.33 -0.01 
GLY  28 -0.34 -3.40 0.00 -3.74 -0.40 -2.89 0.00 -3.29 -0.45 
THR 121 -1.70 2.18 0.00 0.48 -0.16 -1.81 0.00 -1.97 2.44 
ASN  27 -2.39 4.25 0.00 1.86 3.82 -3.11 -0.03 0.68 1.18 
TYR  24 -0.15 2.25 0.00 2.10 -2.71 5.94 -0.05 3.18 -1.08 
GLY 133 -0.21 3.30 0.00 3.09 -0.25 3.55 0.00 3.30 -0.22 
LEU 118 -0.33 3.65 0.00 3.32 -0.52 3.96 0.00 3.44 -0.12 
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Table S3-8 – Per-residue energetic contributions in the FGF2-FGFR1/heparin-A predicted (left) and crystal (right) 
structures for chain C. [PDB: 1FQ9, res. 3.00 Å, RMSD: 1.51/0.75 Å]. 
 
Docked Crystal 
  Residue VdW Coulomb H Bond NonBond VdW Coulomb H Bond NonBond ΔNonBond 
C
ha
in
 C
 
LYS 177 7.03 -159.17 -8.16 -160.30 5.72 -158.41 -1.26 -153.95 -6.35 
LYS 175 0.73 -149.86 -4.69 -153.82 2.31 -130.03 -5.88 -133.60 -20.22 
LYS 163 6.37 -132.42 -6.11 -132.16 1.23 -132.09 -0.39 -131.25 -0.91 
LYS 160 0.37 -131.48 0.00 -131.12 -1.30 -129.72 -0.02 -131.03 -0.08 
ARG 209 -0.44 -117.34 -4.40 -122.18 -0.82 -120.14 0.00 -120.97 -1.21 
LYS 172 -0.78 -118.38 0.00 -119.16 -0.04 -70.04 0.00 -70.08 -49.08 
LYS 207 -0.04 -71.70 0.00 -71.75 -0.04 -61.48 0.00 -61.53 -10.22 
HSE 166 5.52 -12.11 -4.86 -11.44 -1.33 -3.41 0.00 -4.74 -6.70 
VAL 174 -0.99 -3.05 0.00 -4.04 -0.41 -2.90 0.00 -3.30 -0.74 
ILE 216 -0.52 -3.02 0.00 -3.54 -0.02 -1.90 0.00 -1.92 -1.62 
SER 219 -0.02 -1.90 0.00 -1.92 -0.02 -1.66 0.00 -1.68 -0.24 
TYR 206 -0.02 -1.58 0.00 -1.60 -0.01 -0.82 0.00 -0.83 -0.76 
VAL 208 -0.02 -0.86 0.00 -0.87 0.00 0.29 0.00 0.29 -1.16 
PRO 199 0.00 0.24 0.00 0.24 0.00 1.09 0.00 1.09 -0.85 
THR 173 -1.59 2.37 0.00 0.79 0.00 1.64 0.00 1.64 -0.85 
GLY 204 0.00 1.13 0.00 1.13 -1.28 3.00 0.00 1.72 -0.59 
GLY 205 0.00 1.63 0.00 1.63 -1.73 3.49 0.00 1.76 -0.13 
TYR 210 -0.02 2.19 0.00 2.18 -0.01 1.86 0.00 1.84 0.33 
ASP 200 0.00 41.39 0.00 41.39 0.00 41.11 0.00 41.10 0.28 
ASP 218 -0.09 78.09 0.00 78.01 -0.08 77.16 0.00 77.08 0.93 
GLU 159 -0.71 115.33 0.00 114.62 -0.45 107.49 0.00 107.04 7.59 
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Table S3-9 – Per-residue energetic contributions in the FGF2-FGFR1/heparin-A predicted (left) and crystal (right) 
structures for chain D. [PDB: 1FQ9, res. 3.00 Å, RMSD: 1.51/0.75 Å].   
 
Table S3-10 – Per-residue energetic contributions in the FGF2-FGFR1/heparin-B predicted (left) and crystal (right) 
structures for chain C. [PDB: 1FQ9, res. 3.00 Å, RMSD: 1.51/0.75 Å]. 
 
Docked Crystal 
  Residue VdW Coulomb H Bond NonBond VdW Coulomb H Bond NonBond ΔNonBond 
C
ha
in
 D
 
LYS 207 7.45 -180.81 -6.56 -179.92 17.13 -171.90 -0.35 -155.12 -24.79 
ARG 209 3.65 -146.18 -5.18 -147.70 -0.83 -117.34 0.00 -118.16 -29.54 
LYS 175 5.98 -126.60 -6.24 -126.87 -0.40 -94.29 0.00 -94.69 -32.18 
LYS 172 -0.12 -79.28 0.00 -79.40 -0.12 -78.00 0.00 -78.11 -1.29 
LYS 177 -0.04 -72.16 0.00 -72.20 -0.03 -70.11 0.00 -70.14 -2.06 
LYS 160 -0.01 -56.66 0.00 -56.66 0.00 -55.42 0.00 -55.42 -1.25 
LYS 163 -0.01 -56.16 0.00 -56.16 -0.01 -55.17 0.00 -55.17 -0.99 
THR 173 3.72 -10.80 -3.54 -10.63 5.19 -10.69 -4.75 -10.26 -0.37 
TYR 210 -0.96 -5.72 0.00 -6.69 -0.25 -5.06 0.00 -5.30 -1.38 
PRO 199 -1.08 -2.70 0.00 -3.77 -0.45 -2.77 0.00 -3.23 -0.55 
HSE 166 -0.01 -2.21 0.00 -2.22 -0.01 -2.10 0.00 -2.11 -0.12 
GLY 205 -0.32 0.09 0.00 -0.23 -0.12 -1.83 0.00 -1.95 1.72 
ILE 216 0.51 -0.44 0.00 0.07 -0.22 0.36 0.00 0.14 -0.07 
TYR 206 -0.82 1.99 0.00 1.18 -0.69 3.14 0.00 2.45 -1.28 
SER 219 -0.10 2.54 0.00 2.44 -0.30 2.83 0.00 2.53 -0.08 
GLY 204 -0.30 2.82 0.00 2.52 -0.14 3.05 0.00 2.91 -0.39 
VAL 174 -0.15 3.01 0.00 2.86 -1.07 4.05 0.00 2.98 -0.12 
VAL 208 -1.09 5.42 -0.55 3.78 20.87 -0.03 0.00 20.85 -17.07 
GLU 159 0.00 43.02 0.00 43.02 0.00 42.22 0.00 42.22 0.80 
ASP 200 -0.29 88.12 0.00 87.83 -0.18 89.15 0.00 88.97 -1.14 
ASP 218 -2.17 129.70 0.00 127.53 -1.74 120.80 0.00 119.06 8.47 
Docked Crystal 
  Residue VdW Coulomb H Bond NonBond VdW Coulomb H Bond NonBond ΔNonBond 
C
ha
in
 C
 
ARG 209 1.18 -211.75 -4.98 -215.55 -5.88 -198.45 -3.76 -208.09 -7.46 
LYS 207 12.57 -210.11 -9.85 -207.39 38.55 -204.68 -1.08 -167.22 -40.17 
LYS 175 7.82 -136.79 -5.80 -134.77 -0.95 -127.70 0.00 -128.65 -6.12 
LYS 177 -0.07 -88.11 0.00 -88.18 -0.06 -87.73 0.00 -87.79 -0.39 
LYS 172 -0.05 -79.78 0.00 -79.83 -0.04 -79.56 0.00 -79.60 -0.23 
LYS 160 -0.01 -76.48 0.00 -76.49 -0.01 -76.64 0.00 -76.65 0.16 
LYS 163 -0.01 -63.13 0.00 -63.14 -0.01 -63.12 0.00 -63.12 -0.02 
TYR 210 1.90 -7.94 -3.75 -9.79 -0.36 -6.01 0.00 -6.37 -3.42 
THR 173 -0.99 -7.60 0.00 -8.59 -0.78 -5.25 0.00 -6.03 -2.56 
VAL 168 -0.01 -1.12 0.00 -1.13 -0.01 -1.10 0.00 -1.11 -0.02 
SER 214 -0.31 0.98 0.00 0.68 -0.25 -1.54 0.00 -1.79 2.47 
HSE 166 -0.01 1.28 0.00 1.28 -0.01 1.35 0.00 1.34 -0.07 
ILE 216 2.12 -0.30 0.00 1.82 51.25 -0.18 0.00 51.07 -49.25 
VAL 174 -0.12 3.36 0.00 3.24 -0.10 3.33 0.00 3.24 0.01 
THR 212 -0.65 4.14 0.00 3.49 -0.55 -1.10 0.00 -1.65 5.14 
VAL 208 -1.18 8.37 0.00 7.19 -0.79 8.04 0.00 7.24 -0.05 
ASP 218 -0.99 148.97 0.00 147.98 -0.74 142.16 0.00 141.42 6.56 
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Table S3-11 – Per-residue energetic contributions in the FGF2-FGFR1/heparin-B predicted (left) and crystal (right) 
structures for chain D. [PDB: 1FQ9, res. 3.00 Å, RMSD: 1.51/0.75 Å]. 
 
Docked Crystal 
  Residue VdW Coulomb H Bond NonBond VdW Coulomb H Bond NonBond ΔNonBond 
C
ha
in
 D
 
LYS 177 8.65 -171.98 -6.19 -169.52 0.20 -174.51 -3.33 -177.64 8.12 
LYS 175 1.59 -162.42 -4.93 -165.76 -2.60 -161.79 -0.16 -164.55 -1.22 
LYS 172 -0.28 -159.18 -0.78 -160.24 -1.62 -158.79 -0.63 -161.05 0.80 
LYS 163 6.54 -157.81 -4.80 -156.06 -1.33 -141.73 -0.02 -143.09 -12.98 
LYS 160 -1.22 -138.51 0.00 -139.73 3.52 -146.18 0.00 -142.67 2.94 
LYS 207 -0.03 -75.10 0.00 -75.13 -0.04 -75.73 0.00 -75.77 0.64 
ARG 209 -0.04 -71.55 0.00 -71.58 -0.05 -72.21 0.00 -72.25 0.67 
HSE 166 5.13 -14.03 -4.53 -13.43 -0.83 -6.97 0.00 -7.80 -5.63 
SER 214 -0.07 -5.85 0.00 -5.92 -0.10 -2.00 0.00 -2.09 -3.82 
VAL 174 -0.95 -3.15 0.00 -4.10 -1.09 -3.17 0.00 -4.26 0.17 
ILE 216 -0.31 -3.34 0.00 -3.64 -0.44 -3.31 0.00 -3.75 0.11 
VAL 168 -0.27 -2.77 0.00 -3.03 -0.33 -2.64 0.00 -2.97 -0.06 
VAL 208 -0.01 -0.83 0.00 -0.84 -0.02 -0.93 0.00 -0.94 0.10 
THR 212 -0.10 1.83 0.00 1.74 -0.13 0.41 0.00 0.28 1.46 
TYR 210 -0.01 1.78 0.00 1.77 -0.01 2.20 0.00 2.19 -0.41 
THR 173 -1.69 7.34 0.00 5.65 -1.89 3.99 0.00 2.10 3.56 
ASP 218 -0.06 83.76 0.00 83.70 -0.07 83.74 0.00 83.68 0.02 
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Table S3-12 – Per-residue energetic contributions in the Antithrombin-III/heparin analog predicted (left) and crystal 
(right) structures. [PDB: 1E03, res. 2.90 Å, RMSD: 0.60 Å]. 
 
Docked Crystal 
  Residue VdW Coulomb H Bond NonBond VdW Coulomb H Bond NonBond ΔNonBond 
C
ha
in
 I 
ARG  47 5.37 -206.85 -10.73 -212.21 5.88 -194.99 -4.73 -193.85 -18.36 
LYS 114 12.38 -211.46 -10.33 -209.40 -5.92 -219.34 -6.42 -231.68 22.28 
LYS  11 3.13 -202.41 -7.42 -206.70 -6.64 -175.36 0.00 -182.00 -24.70 
ARG  46 9.21 -187.90 -8.44 -187.12 0.31 -171.42 -1.86 -172.98 -14.15 
ARG  13 9.47 -177.67 -12.91 -181.11 -0.70 -117.01 -1.69 -119.39 -61.71 
LYS 125 -1.21 -134.22 0.00 -135.43 176.01 -192.82 -0.26 -17.07 -118.36 
ARG 129 4.95 -129.62 -8.03 -132.71 -0.61 -120.34 -2.08 -123.03 -9.68 
ARG  24 -0.29 -95.38 0.00 -95.67 -0.16 -99.79 0.00 -99.95 4.29 
ARG 132 -0.15 -93.62 0.00 -93.77 -0.36 -100.85 0.00 -101.21 7.44 
ASN  45 -2.51 -17.11 -5.46 -25.08 -4.27 -15.33 -4.67 -24.27 -0.81 
SER 112 -1.18 -11.59 0.00 -12.77 -1.47 1.62 0.00 0.16 -12.93 
PRO  12 -1.66 -8.21 0.00 -9.87 3.69 -10.49 0.00 -6.80 -3.07 
THR  44 -4.47 -3.49 0.00 -7.96 -2.79 0.12 0.00 -2.67 -5.29 
ALA  43 -3.12 -4.65 0.00 -7.77 -3.92 -1.74 0.00 -5.66 -2.12 
VAL  48 -1.15 -5.49 0.00 -6.64 0.26 -6.05 0.00 -5.79 -0.86 
PHE 122 -1.04 -1.68 0.00 -2.72 0.26 -1.98 0.00 -1.71 -1.01 
ILE  40 -0.40 -1.93 0.00 -2.33 -0.29 -2.29 0.00 -2.57 0.25 
PHE 121 -0.37 -1.23 0.00 -1.60 -0.72 -1.42 0.00 -2.14 0.54 
LEU 126 -0.17 -0.39 0.00 -0.56 -0.31 0.04 0.00 -0.27 -0.29 
LEU 417 -0.20 -0.32 0.00 -0.53 -0.24 -0.48 0.00 -0.72 0.20 
GLN 118 -0.23 0.24 0.00 0.01 -0.50 -4.03 0.00 -4.53 4.55 
THR 115 -0.42 0.54 0.00 0.12 -0.42 3.03 0.00 2.61 -2.49 
PRO  41 -0.26 5.91 0.00 5.65 -0.17 4.70 0.00 4.53 1.12 
GLU  42 -0.54 79.06 0.00 78.53 -0.39 89.43 0.00 89.04 -10.51 
GLU 113 1.90 92.68 -1.04 93.55 11.78 97.20 0.00 108.98 -15.43 
ASP  14 -0.11 107.49 0.00 107.38 -0.30 116.97 0.00 116.66 -9.29 
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Figure S3-14 – RPTPσ.  (A) Ig1 and Ig2 domains of RPTPσ. (B) Electrostatic potential surface. (C-F) Predicted structures 
of CS-A, CS-D, CS-E, and heparin after docking and molecular dynamics. 
A 
B 
C 
D 
E 
F 
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Figure S3-15 – Predicted structure of CS-E hexamer (magenta) bound to RPTPσ with 5 Å binding site shown (cyan).  
Dashed lines indicate hydrogen bonding and salt bridges between ligand and protein. 
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Figure S3-16 – Predicted structure of heparin hexamer (magenta) bound to RPTPσ with 5 Å binding site shown (cyan). 
Dashed lines indicate hydrogen bonding and salt bridges between ligand and protein. 
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Table S3-13 – Per-residue energetic contributions in the predicted RPTPσ/CS-A (left) and RPTPσ/CS-D (right) 
structures. 
 
CS-A CS-D 
Residue VdW Coulomb H Bond NonBond VdW Coulomb H Bond NonBond 
ARG  77 2.59 -109.82 -8.26 -115.50 2.85 -152.95 -10.80 -160.91 
LYS  68 9.11 -108.48 -12.32 -111.69 -0.54 -100.52 0.00 -101.06 
ARG 100 -2.41 -90.30 -2.04 -94.75 11.00 -174.16 -25.17 -188.33 
ARG  97 9.71 -89.82 -11.85 -91.97 -0.68 -134.41 -4.42 -139.50 
LYS  71 -1.67 -85.86 0.00 -87.54 14.25 -141.64 -11.80 -139.20 
LYS  69 2.01 -99.90 -6.62 -104.51 -0.19 -76.14 0.00 -76.33 
LYS  72 -- -- -- -- -0.46 -75.57 0.00 -76.03 
GLN  76 -1.67 -7.74 -4.48 -13.89 1.86 -16.06 -8.45 -22.65 
ASN  74 -0.86 2.13 0.00 1.27 -0.30 -0.29 -5.86 -6.45 
SER  75 4.90 -12.36 -4.75 -12.21 -2.31 -6.93 0.00 -9.24 
ASN 103 -1.20 -2.24 0.00 -3.44 -0.15 -1.06 0.00 -1.20 
GLU 102 -0.23 48.03 0.00 47.80 -- -- -- -- 
GLY  70 -- -- -- -- -- -- -- -- 
PRO  95 -- -- -- -- -1.05 1.32 0.00 0.27 
PRO  99 -- -- -- -- -- -- -- -- 
THR  98 -- -- -- -- -0.19 1.83 0.00 1.65 
VAL  73 -0.82 -2.94 0.00 -3.77 -0.30 -1.35 0.00 -1.65 
TYR 105 -- -- -- -- -0.09 -2.46 0.00 -2.55 
PHE  78 -3.66 -1.37 0.00 -5.03 -- -- -- -- 
ASP 101 -0.63 75.50 0.00 74.88 -- -- -- -- 
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Table S3-14 – Per-residue energetic contributions in the predicted RPTPσ/CS-E (left) and RPTPσ/heparin (right) 
structures. 
 
 
Figure S3-17 – Electrostatic potential surfaces of (A) NgR1, (B) NgR2, and (C) NgR3.  Note the lack of positive charge on 
NgR2, but strong positive charge on NgR1 and NgR3. 
CS-E heparin 
Residue VdW Coulomb H Bond NonBond VdW Coulomb H Bond NonBond 
ARG  77 11.74 -158.46 -17.21 -163.92 0.89 -180.82 -7.26 -187.18 
LYS  68 10.98 -158.86 -10.24 -158.12 -0.60 -170.34 -1.68 -172.61 
ARG 100 -0.66 -139.54 -9.43 -149.63 3.44 -208.70 -9.97 -215.23 
ARG  97 1.84 -137.33 -5.15 -140.64 2.01 -180.78 -8.27 -187.04 
LYS  71 -2.11 -131.74 0.00 -133.86 4.10 -223.34 -3.40 -222.65 
LYS  69 3.46 -115.00 -5.67 -117.21 -1.69 -127.16 0.00 -128.85 
LYS  72 -0.37 -65.91 0.00 -66.28 -- -- -- -- 
GLN  76 5.83 -20.07 -12.97 -27.22 -0.17 -5.26 0.00 -5.43 
ASN  74 2.57 -15.72 -10.33 -23.48 -0.22 -1.46 0.00 -1.68 
SER  75 -1.95 -10.28 -0.59 -12.83 -0.85 -7.68 -0.18 -8.71 
ASN 103 -1.49 -9.18 0.00 -10.67 -0.26 -9.19 0.00 -9.45 
GLU 102 -- -- -- -- -- -- -- -- 
GLY  70 -- -- -- -- -0.15 0.74 0.00 0.59 
PRO  95 -- -- -- -- -0.54 4.62 0.00 4.08 
PRO  99 -- -- -- -- -1.04 -2.44 0.00 -3.47 
THR  98 -- -- -- -- -0.28 3.73 0.00 3.45 
VAL  73 -2.38 -5.93 0.00 -8.31 -- -- -- -- 
TYR 105 3.55 -6.81 -4.76 -8.02 -- -- -- -- 
PHE  78 -3.37 1.18 0.00 -2.19 -1.31 -0.46 0.00 -1.77 
ASP 101 -1.75 97.79 0.00 96.04 -- -- -- -- 
A – NgR1 B – NgR2 C – NgR3 
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Figure S3-18 – NgR1.  (A) Structure of NgR1. (B) Electrostatic potential surface showing strong positive charge. (C-F) 
Predicted structures of CS-A, CS-D, CS-E, and heparin after docking and molecular dynamics. (G-H) Detailed view of CS-
E and heparin predicted structures. 
A
B
C
D
E
F
G
H
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Figure S3-19 – Detail of predicted NgR1/CS-A structure after docking and dynamics with CS-A hexamer (magenta) and 5 
Å binding site (cyan) shown.  Dashed lines indicate hydrogen bonding and salt bridges between ligand and protein.  Overall 
placement on protein shown in inset. 
NgR1/CS-A 
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Figure S3-20 – Detail of predicted NgR1/CS-D structure after docking and dynamics with CS-D hexamer (magenta) and 5 
Å binding site (cyan) shown.  Dashed lines indicate hydrogen bonding and salt bridges between ligand and protein. 
 
Figure S3-21 – Detail of predicted NgR1/CS-E structure after docking and dynamics with CS-E hexamer (magenta) and 5 
Å binding site (cyan) shown.  Dashed lines indicate hydrogen bonding and salt bridges between ligand and protein. 
NgR1/CS-D 
NgR1/CS-E 
  
98 
 
Figure S3-22 – Detail of predicted NgR1/heparin structure after docking and dynamics with heparin hexamer (magenta) 
and 5 Å binding site (cyan) shown.  Dashed lines indicate hydrogen bonding and salt bridges between ligand and protein. 
NgR1/Heparin 
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Table S3-15 – Per-residue energetic contributions in the predicted NgR1 structures for CS-A, CS-D, CS-E, and heparin. 
 
 
Figure S3-23 – NgR3.  (A) Structure of NgR3. (B) Electrostatic potential surface. (C-F) Predicted structures of CS-A, CS-D, 
CS-E, and heparin after docking and molecular dynamics. (G-H) Detailed view of CS-E and heparin predicted structures. 
CS-A	 CS-D	 CS-E	 Heparin	
Residue	 VdW	 Coulomb	 H	Bond	 NonBond	 VdW	 Coulomb	 H	Bond	 NonBond	 VdW	 Coulomb	 H	Bond	 NonBond	 VdW	 Coulomb	 H	Bond	 NonBond	
ARG	 390	 6.94	 -90.88	 -13.23	 -97.17	 2.15	 -136.95	 -11.48	 -146.28	 -1.11	 -61.48	 0.00	 -62.59	 5.12	 -213.83	 -16.07	 -224.78	
ARG	 392	 -2.73	 -107.51	 -5.79	 -116.04	 -2.26	 -126.71	 -8.96	 -137.93	 -0.19	 -158.71	 -14.92	 -173.82	 2.77	 -191.60	 -10.23	 -199.06	
ARG	 406	 -2.67	 -96.20	 -7.45	 -106.33	 4.79	 -116.69	 -8.19	 -120.09	 2.55	 -131.51	 -12.53	 -141.50	 -1.21	 -176.87	 -6.87	 -184.95	
ARG	 402	 -3.57	 -69.97	 0.00	 -73.53	 0.76	 -120.34	 -4.53	 -124.10	 3.02	 -147.77	 -12.85	 -157.59	 0.82	 -151.54	 -9.09	 -159.81	
ARG	 400	 -0.48	 -96.72	 -5.19	 -102.39	 8.97	 -144.72	 -15.76	 -151.51	 -0.73	 -98.90	 0.00	 -99.63	 4.04	 -142.10	 -5.53	 -143.59	
ARG	 391	 -2.06	 -111.17	 -8.33	 -121.56	 1.17	 -142.38	 -7.89	 -149.09	 -1.38	 -105.45	 0.00	 -106.83	 -1.06	 -134.39	 0.00	 -135.44	
ARG	 397	 -0.25	 -56.79	 0.00	 -57.04	 -1.74	 -101.89	 -0.03	 -103.66	 -0.15	 -72.85	 0.00	 -73.00	 -0.06	 -96.30	 0.00	 -96.36	
LYS	 398	 -0.40	 -40.49	 0.00	 -40.89	 -0.78	 -81.71	 0.00	 -82.49	 -0.14	 -58.40	 0.00	 -58.54	 -0.06	 -68.64	 0.00	 -68.70	
PRO	 389	 -4.08	 -5.91	 0.00	 -9.99	 -4.13	 -4.22	 0.00	 -8.34	 -0.33	 -3.98	 0.00	 -4.31	 -0.36	 -4.12	 0.00	 -4.48	
GLY	 408	 -1.82	 -0.24	 0.00	 -2.06	 -0.81	 -5.51	 0.00	 -6.32	 -0.09	 -4.24	 0.00	 -4.33	 -0.07	 -4.17	 0.00	 -4.24	
GLY	 388	 -0.62	 -3.62	 0.00	 -4.24	 -0.96	 -6.68	 0.00	 -7.64	 -0.04	 -3.15	 0.00	 -3.19	 -0.03	 -4.10	 0.00	 -4.13	
CYS	 405	 -1.71	 0.31	 -2.35	 -3.75	 -0.20	 -5.66	 -2.02	 -7.88	 -0.01	 -8.79	 0.00	 -8.80	 -3.89	 -0.16	 0.00	 -4.05	
ASN	 399	 -1.35	 -5.54	 0.00	 -6.89	 -1.93	 1.27	 0.00	 -0.65	 -0.19	 -4.50	 0.00	 -4.70	 -0.31	 -3.64	 0.00	 -3.95	
PHE	 384	 -0.69	 -1.25	 0.00	 -1.94	 -0.23	 -2.07	 0.00	 -2.30	 -0.03	 -1.51	 0.00	 -1.55	 -0.07	 -2.90	 0.00	 -2.97	
LEU	 407	 -0.98	 0.71	 0.00	 -0.27	 -0.25	 -1.87	 0.00	 -2.12	 -0.27	 -1.86	 0.00	 -2.14	 -0.07	 -1.97	 0.00	 -2.04	
GLY	 394	 1.03	 -2.84	 0.00	 -1.81	 -0.56	 0.65	 0.00	 0.09	 -0.50	 0.68	 0.00	 0.18	 -0.05	 -1.33	 0.00	 -1.38	
CYS	 395	 -2.02	 -1.44	 0.00	 -3.46	 -0.43	 -9.15	 0.00	 -9.58	 -2.79	 -12.58	 0.00	 -15.37	 -0.65	 -0.26	 0.00	 -0.91	
SER	 344	 -0.83	 -0.23	 0.00	 -1.07	 -0.11	 -0.55	 0.00	 -0.66	 -0.01	 -1.48	 0.00	 -1.49	 -0.02	 -0.19	 0.00	 -0.21	
THR	 444	 0.00	 -0.53	 0.00	 -0.53	 -0.01	 1.78	 0.00	 1.78	 0.00	 -0.46	 0.00	 -0.46	 0.00	 0.64	 0.00	 0.64	
ALA	 410	 -0.17	 -0.76	 0.00	 -0.93	 -0.24	 0.61	 0.00	 0.37	 -0.02	 -0.05	 0.00	 -0.07	 -0.03	 1.06	 0.00	 1.03	
THR	 386	 -0.20	 0.59	 0.00	 0.39	 -0.06	 1.06	 0.00	 1.00	 -0.01	 1.22	 0.00	 1.21	 -0.01	 1.16	 0.00	 1.15	
HSE	 404	 -0.48	 1.27	 0.00	 0.79	 -0.60	 2.33	 0.00	 1.73	 -0.29	 0.25	 0.00	 -0.04	 -0.23	 1.87	 0.00	 1.63	
GLN	 409	 -0.49	 1.79	 0.00	 1.30	 -1.17	 9.18	 0.00	 8.01	 -0.07	 3.92	 0.00	 3.85	 -0.07	 2.02	 0.00	 1.95	
PRO	 345	 -0.13	 0.77	 0.00	 0.64	 -0.04	 1.85	 0.00	 1.82	 0.00	 1.29	 0.00	 1.29	 -0.01	 2.08	 0.00	 2.08	
GLY	 342	 -0.99	 -1.11	 0.00	 -2.10	 -0.04	 2.58	 0.00	 2.55	 -0.01	 1.93	 0.00	 1.93	 -0.02	 2.20	 0.00	 2.18	
THR	 401	 -0.66	 2.74	 0.00	 2.08	 -0.46	 4.98	 0.00	 4.52	 -0.37	 3.92	 0.00	 3.55	 -0.72	 3.17	 0.00	 2.45	
SER	 396	 -0.18	 3.43	 0.00	 3.25	 0.59	 5.47	 -3.85	 2.21	 3.30	 -2.21	 -4.89	 -3.80	 -0.18	 2.69	 0.00	 2.51	
PRO	 393	 -3.03	 4.64	 0.00	 1.61	 -0.79	 7.05	 0.00	 6.26	 -0.40	 7.33	 0.00	 6.92	 -0.24	 5.85	 0.00	 5.61	
SER	 403	 -0.18	 3.43	 0.00	 3.25	 -0.19	 2.81	 0.00	 2.61	 -1.02	 1.80	 0.00	 0.78	 -0.35	 6.34	 0.00	 5.99	
ASP	 343	 -1.62	 48.13	 0.00	 46.51	 -0.07	 71.82	 0.00	 71.74	 -0.01	 61.99	 0.00	 61.98	 -0.02	 82.58	 0.00	 82.56	
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Figure S3-24 – Detail of predicted NgR3/CS-A structure after docking and dynamics with CS-A hexamer (magenta) and 5 
Å binding site (cyan) shown.  Dashed lines indicate hydrogen bonding and salt bridges between ligand and protein. 
NgR3/CS-A 
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Figure S3-25 – Detail of predicted NgR3/CS-D structure after docking and dynamics with CS-D hexamer (magenta) and 5 
Å binding site (cyan) shown.  Dashed lines indicate hydrogen bonding and salt bridges between ligand and protein. 
NgR3/CS-D 
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Figure S3-26 – Detail of predicted NgR3/CS-E structure after docking and dynamics with CS-E hexamer (magenta) and 5 
Å binding site (cyan) shown.  Dashed lines indicate hydrogen bonding and salt bridges between ligand and protein. 
NgR3/CS-E 
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Figure S3-27 – Detail of predicted NgR3/heparin structure after docking and dynamics with heparin hexamer (magenta) 
and 5 Å binding site (cyan) shown.  Dashed lines indicate hydrogen bonding and salt bridges between ligand and protein. 
NgR3/Heparin 
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Table S3-16 – Per-residue energetic contributions in the predicted NgR3 structures for CS-A, CS-D, CS-E, and 
heparin. 
 
VdW Coulomb H	Bond NonBond VdW Coulomb H	Bond NonBond VdW Coulomb H	Bond NonBond VdW Coulomb H	Bond NonBond
LYS 383 4.11 -102.12 -2.70 -100.71 0.45 -152.91 -4.15 -156.61 6.52 -162.33 -9.44 -165.24 7.58 -206.62 -11.23 -210.27
ARG 380 -0.04 -40.12 0.00 -40.16 -1.06 -102.20 0.00 -103.26 -1.20 -119.85 -5.80 -126.85 3.48 -182.45 -7.59 -186.56
LYS 381 -0.17 -52.67 0.00 -52.84 0.75 -138.39 -4.12 -141.76 4.02 -139.02 -10.71 -145.71 7.81 -180.38 -6.68 -179.25
ARG 330 -0.84 -63.93 0.00 -64.77 -2.80 -102.67 0.00 -105.47 -0.31 -153.39 -11.01 -164.70 2.79 -158.26 -5.44 -160.90
ARG 340 -2.65 -68.57 0.00 -71.22 1.84 -118.19 -5.24 -121.59 -0.29 -83.03 0.00 -83.32 -1.34 -156.72 -2.65 -160.71
LYS 331 -0.27 -98.70 -4.75 -103.72 3.13 -123.36 -5.79 -126.02 -0.63 -74.84 0.00 -75.48 -0.71 -153.93 -0.76 -155.40
LYS 334 -1.13 -89.69 -4.68 -95.50 -2.39 -97.83 0.00 -100.22 -2.53 -141.48 -1.46 -145.47 -3.30 -134.35 0.00 -137.65
LYS 379 -0.84 -81.40 -0.02 -82.25 -0.17 -67.58 0.00 -67.74 -0.37 -84.61 0.00 -84.99 -1.05 -130.60 0.00 -131.66
ARG 342 2.01 -72.80 -6.37 -77.17 -2.08 -104.32 -3.28 -109.68 -0.09 -68.84 0.00 -68.93 -0.81 -118.99 0.00 -119.80
ARG 326 -1.18 -62.89 0.00 -64.07 -0.84 -92.99 0.00 -93.83 -2.41 -72.84 0.00 -75.25 -0.08 -97.25 0.00 -97.33
ASN 335 -1.84 0.07 0.00 -1.77 2.32 -9.47 -4.60 -11.75 -1.99 -9.78 -3.64 -15.41 -0.19 -12.30 -6.78 -19.27
ASN 338 -1.39 -2.82 -0.16 -4.37 -1.61 -2.72 -0.08 -4.41 -1.12 -2.24 0.00 -3.37 -1.17 -3.49 0.00 -4.66
PRO 362 -0.25 -0.75 0.00 -1.00 -0.20 -2.05 0.00 -2.25 -0.02 -1.54 0.00 -1.57 -0.02 -2.42 0.00 -2.44
PRO 327 -0.88 -3.14 0.00 -4.01 -0.87 -3.83 0.00 -4.70 -3.57 0.38 0.00 -3.18 -0.22 -1.95 0.00 -2.17
GLY 333 0.34 -0.67 -4.29 -4.63 -1.59 -1.25 -3.92 -6.77 -2.38 4.27 0.00 1.89 -1.51 -0.23 0.00 -1.74
GLY 382 -0.09 0.75 0.00 0.66 -0.12 2.17 0.00 2.05 -1.28 1.34 0.00 0.06 -0.25 -1.36 0.00 -1.61
ILE 345 -0.85 -0.11 0.00 -0.96 -1.88 -0.42 0.00 -2.30 -0.12 -0.55 0.00 -0.67 -0.08 -0.78 0.00 -0.86
ALA 350 -0.30 -2.38 0.00 -2.68 -0.12 -1.27 0.00 -1.39 -0.13 -0.71 0.00 -0.84 -0.02 -0.79 0.00 -0.81
ASN 341 -1.36 0.73 0.00 -0.63 -0.15 2.42 0.00 2.27 -0.04 0.79 0.00 0.75 -0.06 0.00 0.00 -0.07
GLY 349 -0.16 -2.75 0.00 -2.91 -0.45 -4.02 0.00 -4.47 -1.21 -2.14 0.00 -3.35 -0.06 0.43 0.00 0.37
PRO 332 -2.68 -0.11 0.00 -2.79 -1.95 -2.37 0.00 -4.32 -0.92 4.48 0.00 3.55 -0.59 1.27 0.00 0.68
PRO 339 -4.19 5.10 0.00 0.92 -0.55 8.20 0.00 7.65 -0.28 5.86 0.00 5.59 -0.26 1.69 0.00 1.43
ALA 348 -0.46 -3.28 0.00 -3.74 -0.29 -2.64 0.00 -2.93 -1.34 -2.64 0.00 -3.97 -0.44 2.12 0.00 1.69
HSE 309 -0.02 -0.37 0.00 -0.40 -0.02 0.60 0.00 0.58 -0.65 -1.57 0.00 -2.21 -0.02 1.89 0.00 1.87
HSE 329 -0.06 0.65 0.00 0.58 -0.27 0.00 0.00 -0.26 -1.25 -1.38 0.00 -2.63 -0.26 3.43 0.00 3.18
PRO 325 -0.44 3.13 0.00 2.69 -0.19 3.21 0.00 3.03 -2.53 -1.17 0.00 -3.70 -0.03 3.36 0.00 3.33
ASP 359 -0.30 64.07 0.00 63.78 -0.04 79.36 0.00 79.32 -0.03 69.11 0.00 69.09 -0.08 100.87 0.00 100.79
Heparin
Residue
CS-A CS-D CS-E
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Table S3-17 – Single residue mutation data for RPTPs.  Values show change in binding energy (kcal/mol) relative to 
wildtype structures.  Values are shown both for the change in hydrogen bonding for the specific mutated residue as well as 
the overall change in the full cavity binding energy.  The cavity binding energy is further separated into hydrogen bonding + 
van der Waals or Coulomb energy. 
 
 
Table S3-18 – Single residue mutation data for NgR1.  Values show change in binding energy (kcal/mol) relative to 
wildtype structures.  Values are shown both for the change in hydrogen bonding for the specific mutated residue as well as 
the overall change in the full cavity binding energy.  The cavity binding energy is further separated into hydrogen bonding + 
van der Waals or Coulomb energy. 
num from to CSA CSD CSE HEP ∆Cav ∆(HB+VDW) ∆Cou ∆Cav ∆(HB+VDW) ∆Cou ∆Cav ∆(HB+VDW) ∆Cou ∆Cav ∆(HB+VDW) ∆Cou
73 V N -1.48 0.00 -6.17 0.00 1.56 -6.53 8.09 5.03 7.96 -2.93 -28.66 3.08 -31.75 -1.41 -2.47 1.07
73 V Q -1.82 0.00 0.00 0.00 -2.36 -5.15 2.78 -3.85 5.70 -9.56 -32.20 -6.47 -25.73 -5.87 -0.20 -5.66
74 N Q 0.00 -4.29 5.91 0.00 -11.00 -3.44 -7.56 13.75 1.60 12.14 14.66 10.45 4.21 2.97 -3.06 6.03
75 S N -1.22 -4.66 -1.17 0.31 -7.17 7.22 -14.40 -35.76 -4.34 -31.41 11.00 1.23 9.78 24.41 0.73 23.69
75 S Q 4.75 -1.11 4.44 0.31 26.31 29.85 -3.54 -28.87 -6.92 -21.96 21.53 24.46 -2.94 21.00 2.33 18.68
76 Q N -1.61 1.19 -1.50 0.00 -9.37 -2.33 -7.04 0.44 -0.59 1.02 2.28 5.24 -2.97 6.07 -1.82 7.89
78 F N -4.58 0.00 0.00 0.00 3.34 0.46 2.89 5.48 5.98 -0.50 -3.23 3.50 -6.73 6.58 1.98 4.60
78 F Q 0.00 0.00 -3.07 0.00 -11.05 -4.91 -6.15 -8.99 4.79 -13.79 -6.42 6.54 -12.97 2.47 -2.04 4.51
103 N Q -1.14 0.00 5.15 -0.04 -13.39 -0.59 -12.80 -22.49 -8.02 -14.47 -6.56 0.38 -6.94 -6.77 -3.88 -2.88
num from to CSA CSD CSE HEP ∆Cav ∆(HB+VDW) ∆Cou ∆Cav ∆(HB+VDW) ∆Cou ∆Cav ∆(HB+VDW) ∆Cou ∆Cav ∆(HB+VDW) ∆Cou
68 K N 7.58 0.00 5.88 9.87 95.67 8.45 87.22 79.75 -5.99 85.73 119.99 -3.28 123.26 137.68 1.17 136.51
68 K Q 7.60 0.00 0.43 9.87 103.11 7.80 95.31 77.89 -4.12 82.01 116.16 -0.89 117.05 160.96 3.13 157.83
69 K N 8.27 0.00 -0.43 0.41 109.55 12.56 96.99 87.95 5.61 82.35 84.90 -3.08 87.97 123.59 -1.29 124.88
69 K Q 8.27 0.00 5.12 0.41 97.91 5.28 92.63 75.40 4.98 70.41 90.73 -5.27 95.99 135.29 -6.80 142.10
71 K N 4.58 4.29 1.68 5.71 78.37 4.92 73.44 84.49 -3.90 88.39 74.38 -1.00 75.38 172.64 -0.70 173.34
71 K Q 6.15 -2.56 0.20 11.24 89.01 13.20 75.81 74.24 -11.41 85.65 72.17 -1.89 74.06 185.03 13.95 171.08
77 R Q 6.96 6.37 6.84 14.14 100.48 5.10 95.38 128.38 3.40 124.98 107.04 -9.98 117.03 163.36 0.66 162.70
77 R N 7.01 0.96 11.82 14.14 94.89 2.33 92.57 130.30 -1.43 131.72 108.53 -10.16 118.69 165.41 0.61 164.81
97 R N 4.59 9.78 -0.96 12.05 100.76 0.66 100.09 123.99 1.22 122.76 121.08 11.91 109.17 189.16 -0.56 189.72
97 R Q 4.59 9.78 -0.05 6.35 91.62 -0.55 92.18 116.85 2.75 114.09 114.11 1.33 112.78 188.49 0.66 187.84
100 R N 12.01 18.70 3.81 15.24 98.76 2.89 95.88 150.09 5.51 144.58 139.31 0.52 138.79 219.62 -1.39 221.02
100 R Q 12.01 23.01 0.71 15.53 91.91 2.23 89.69 132.35 2.97 129.37 112.37 3.65 108.72 221.74 1.56 220.19
PTPS	Increased	Binding
PTPS	Residue Per-Res	∆HBond CSA	Cavity CSD	Cavity CSE	Cavity HEP	Cavity
PTPS	Decreased	Binding
PTPS	Residue Per-Res	∆HBond CSA	Cavity CSD	Cavity CSE	Cavity HEP	Cavity
num from to CSA CSD CSE HEP ∆Cav ∆(HB+VDW) ∆Cou ∆Cav ∆(HB+VDW) ∆Cou ∆Cav ∆(HB+VDW) ∆Cou ∆Cav ∆(HB+VDW) ∆Cou
395 C Q -5.33 0.00 -4.87 0.00 -7.24 2.09 -9.33 3.60 -1.74 5.34 8.95 0.38 8.57 6.30 -3.63 9.93
396 S N 0.00 -1.73 -6.06 0.00 -3.19 3.57 -6.76 -15.44 -3.64 -11.80 9.88 3.95 5.93 10.94 -3.36 14.31
396 S Q 0.00 4.38 -0.05 -4.85 -6.51 3.69 -10.21 -0.97 1.83 -2.81 15.97 5.70 10.27 -13.35 -5.15 -8.19
399 N Q 4.67 -3.26 0.00 0.00 2.86 2.29 0.58 -7.57 -2.71 -4.86 2.18 -0.67 2.85 -47.06 -1.26 -45.80
403 S Q 0.00 0.00 -5.22 0.00 4.39 4.40 0.00 -3.76 -2.31 -1.45 5.82 2.99 2.84 -1.31 -4.93 3.62
405 C N -6.52 -4.36 -0.79 -3.27 -8.64 5.99 -14.62 -24.39 -5.79 -18.61 -0.64 -0.16 -0.47 -0.03 -7.67 7.65
405 C Q 0.00 -1.60 -6.10 0.00 -4.76 8.05 -12.81 -4.87 5.03 -9.90 -3.39 -0.36 -3.04 -0.92 -5.56 4.64
num from to CSA CSD CSE HEP ∆Cav ∆(HB+VDW) ∆Cou ∆Cav ∆(HB+VDW) ∆Cou ∆Cav ∆(HB+VDW) ∆Cou ∆Cav ∆(HB+VDW) ∆Cou
390 R Q 0.86 8.12 0.00 14.17 83.82 3.55 80.28 127.85 4.00 123.84 74.90 -2.34 77.24 216.92 -6.24 223.17
390 R N 3.65 7.85 0.00 20.17 91.45 4.43 87.03 129.28 7.46 121.83 103.46 1.07 102.40 214.66 5.94 208.73
391 R N 12.39 1.33 4.80 0.00 111.02 12.01 99.03 117.11 -3.64 120.74 133.74 3.22 130.51 104.52 -5.12 109.65
391 R Q 12.39 5.69 4.80 0.00 81.87 1.91 79.96 108.81 6.44 102.37 130.43 2.71 127.72 116.57 -6.14 122.71
392 R N 5.47 -0.86 10.62 6.61 87.18 6.33 80.86 120.25 11.02 109.24 165.18 11.93 153.25 176.91 4.80 172.12
392 R Q 5.93 -0.64 10.64 7.72 88.87 5.06 83.81 111.70 3.80 107.91 165.48 10.73 154.75 175.74 3.43 172.31
400 R N 0.88 15.38 0.00 5.59 75.35 3.35 72.00 140.99 10.79 130.20 95.87 -1.00 96.87 141.97 -4.20 146.17
400 R Q 0.95 11.95 0.00 5.57 88.95 9.99 78.97 135.65 8.85 126.80 93.43 -0.12 93.56 108.39 -2.58 110.97
402 R Q 7.41 5.08 12.90 4.13 78.45 8.42 70.03 107.96 -4.30 112.26 147.99 4.21 143.78 142.76 -4.02 146.78
402 R N 7.47 6.67 0.70 2.92 84.77 9.26 75.52 110.69 -4.12 114.81 144.72 3.64 141.08 149.66 -3.21 152.87
406 R Q 6.16 2.32 13.46 5.97 91.65 9.39 82.27 86.91 -5.04 91.95 136.94 2.12 134.82 167.79 2.68 165.11
406 R N 7.34 4.44 12.49 5.97 103.23 11.66 91.57 97.02 3.78 93.24 135.69 1.72 133.98 181.99 -1.47 183.46
CSD	Cavity CSE	Cavity HEP	Cavity
NGR1	Decreased	Binding
NGR1	Residue Per-Res	∆HBond CSA	Cavity CSD	Cavity CSE	Cavity HEP	Cavity
NGR1	Residue Per-Res	∆HBond
NGR1	Increased	Binding
CSA	Cavity
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Table S3-19 – Single residue mutation data for NgR3.  Values show change in binding energy (kcal/mol) relative to 
wildtype structures.  Values are shown both for the change in hydrogen bonding for the specific mutated residue as well as 
the overall change in the full cavity binding energy.  The cavity binding energy is further separated into hydrogen bonding + 
van der Waals or Coulomb energy. 
 
num from to CSA CSD CSE HEP ∆Cav ∆(HB+VDW) ∆Cou ∆Cav ∆(HB+VDW) ∆Cou ∆Cav ∆(HB+VDW) ∆Cou ∆Cav ∆(HB+VDW) ∆Cou
338 N Q 1.43 0.06 3.53 -5.31 -4.84 2.39 -7.23 6.70 0.74 5.96 18.28 -2.09 20.37 0.10 1.74 -1.64
345 I Q -4.24 -5.59 0.00 0.00 -3.12 -0.93 -2.20 0.80 -3.97 4.78 -10.18 -7.76 -2.41 -0.10 -0.19 0.08
348 A N -4.60 0.00 -0.78 -2.15 -12.91 -2.87 -10.04 -5.07 -2.65 -2.42 -5.76 -1.24 -4.51 -12.19 -3.71 -8.48
num from to CSA CSD CSE HEP ∆Cav ∆(HB+VDW) ∆Cou ∆Cav ∆(HB+VDW) ∆Cou ∆Cav ∆(HB+VDW) ∆Cou ∆Cav ∆(HB+VDW) ∆Cou
330 R N 0.74 -1.09 9.03 0.08 84.09 9.33 74.77 49.41 -4.51 53.92 149.89 2.24 147.65 125.52 -3.79 129.32
330 R Q 0.74 -2.10 7.54 -0.17 84.81 10.32 74.49 28.03 -5.77 33.80 152.89 2.27 150.63 127.01 -5.33 132.33
331 K Q 4.31 5.31 1.87 -2.08 92.34 0.99 91.35 25.97 -7.63 33.60 105.28 6.51 98.78 155.28 -2.14 157.42
331 K N 7.53 5.75 1.87 -6.82 101.31 7.32 94.00 31.23 -5.72 36.95 100.70 6.15 94.55 148.88 -1.89 150.77
334 K N 2.01 -6.09 9.00 0.00 70.93 -2.08 73.02 70.93 -6.27 77.20 154.48 -2.05 156.53 119.55 -2.40 121.96
334 K Q 6.57 0.00 3.57 0.00 53.70 1.07 52.63 93.72 -3.94 97.67 102.98 -2.46 105.44 130.15 -0.69 130.84
340 R N 0.00 -1.29 0.00 5.17 64.44 1.69 62.74 117.17 -4.79 121.96 73.59 -5.51 79.09 112.55 -10.32 122.87
340 R Q 0.00 -1.28 0.00 5.17 64.45 0.34 64.11 72.83 -7.89 80.72 77.98 -11.87 89.85 120.72 -7.44 128.16
342 R N 8.86 16.64 5.66 0.00 71.30 4.52 66.77 128.14 0.11 128.03 95.01 -5.88 100.89 108.88 -8.34 117.22
342 R Q 8.86 16.07 5.66 0.00 63.84 3.86 59.98 126.70 -0.15 126.85 92.95 -4.70 97.65 108.36 -6.29 114.65
379 K N 0.00 0.00 0.00 5.58 3.64 -4.34 7.99 76.86 -2.33 79.19 82.12 -1.28 83.39 158.63 2.23 156.40
379 K Q 0.00 0.00 0.00 5.58 11.27 2.03 9.24 72.12 -1.96 74.08 84.91 -0.05 84.96 158.55 -1.94 160.48
380 R N 0.00 5.43 0.59 3.93 42.61 -0.06 42.68 51.23 0.39 50.85 66.95 -3.91 70.86 188.74 -3.93 192.67
380 R Q 0.00 5.43 2.81 1.21 35.33 0.26 35.08 45.62 -0.61 46.23 69.83 -10.08 79.91 196.39 -3.00 199.40
381 K N 0.00 4.69 8.58 1.68 56.14 2.87 53.27 84.96 -2.92 87.89 119.97 -5.89 125.86 146.31 -14.85 161.17
381 K Q 0.00 4.69 8.27 -7.65 47.50 0.85 46.65 110.48 -0.09 110.57 120.14 -4.00 124.14 137.24 -17.81 155.05
383 K Q -5.14 6.10 2.09 6.77 42.26 2.69 39.58 63.75 -7.34 71.09 95.05 -3.91 98.96 154.07 -9.80 163.87
383 K N 0.00 6.10 10.92 7.95 42.16 1.41 40.75 60.25 -2.41 62.66 92.99 -2.73 95.71 176.79 -5.68 182.47
HEP	Cavity
NGR3	Increased	Binding
NGR3	Residue Per-Res	∆HBond CSA	Cavity CSD	Cavity CSE	Cavity HEP	Cavity
NGR3	Decreased	Binding
NGR3	Residue Per-Res	∆HBond CSA	Cavity CSD	Cavity CSE	Cavity
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